TY 2022 Form 990

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
(1) PATRICIA M STEWART...................................................................... CHAIR	10.00 .................	X	X		0	0
(2) CECILIA ARRADAZA...................................................................... VICE CHAIR	6.00 .................	X	X		0	0
(3) MADDY DYCHTWALD...................................................................... SECRETARY	6.00 .................	X	X		0	0
(4) ETHAN TREESE...................................................................... TREASURER - UNTIL 06/2022	2.00 .................	X	X		0	0
(5) EDWARD FINLEY DIRECTOR...................................................................... TREASURER - AS OF 06/2022	8.00 .................	X	X		0	0
(6) PAUL CAMPBELL...................................................................... DIRECTOR	5.00 .................	X			0	0
(7) SHAWA GOTTLIEB...................................................................... DIRECTOR	5.00 .................	X			0	0
(8) DANA GRIFFIN...................................................................... DIRECTOR	5.00 .................	X			0	0
(9) SCOTT KAISER MD...................................................................... DIRECTOR	5.00 .................	X			0	0
(10) TONYA MATTHEWS PHD...................................................................... DIRECTOR	5.00 .................	X			0	0
(11) ERIC SIEMERS MD...................................................................... DIRECTOR - UNTIL 06/2022	2.00 .................	X			0	0
(12) JAN M STOUFFER PHD...................................................................... DIRECTOR	6.00 .................	X			0	0
(13) STACY PAGOS HALLER...................................................................... PRESIDENT/CEO	45.00 .................		X		440,796	52,228
(14) NANCY LYNN...................................................................... SR. VP STRATEGIC PARTNERSHIPS	45.00 .................			X	250,394	55,303
(15) R BRIAN ELDERTON...................................................................... SR. VP, DEVELOPMENT	45.00 .................			X	243,178	46,740
(16) DAVID F MARKS CPA CMA...................................................................... VP, FINANCE & ADMINISTRATION	45.00 .................			X	166,931	58,076
(17) DIANE BOVENKAMP PHD...................................................................... VP, SCIENTIFIC AFFAIRS	45.00 .................			X	182,082	21,178

(A) Name and business address	(B) Description of services	(C) Compensation
RKD GROUP 35 PARKWOOD DRIVE SUITE 160 HOPKINTON,MA01748	PUBLIC AWARENESS CONSUL. & MATERIALS	9,849,026
ALLEGIANCE GROUP 2300 CLARENDON BLVD SUITE 925 ARLINGTON,VA22201	ONLINE PUBLIC AWARENESS CONSULTING	1,890,997
ADSTRA LLC 750 COLLEGE ROAD EAST SUITE 201 PRINCETON,NJ08540	LIST RENTAL	1,174,435
DATA MANAGEMENT INC 160 STONE STREET STONEVILLE,NC27048	DATABASE MANAGEMENT	298,773
GOOGLE LLC 1600 AMPHITHEATRE PKWY MOUNTAIN VIEW,CA94043	PUBLIC AWARENESS ADVERTISING	222,954
2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 14

- TIN:

SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
right arrow

Attach to Form 990 or Form 990-EZ.
right arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E (Form 990).)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An agricultural research organization described in 170(b)(1)(A)(ix) operated in conjunction with a land-grant college or university or a non-land grant college of agriculture. See instructions. Enter the name, city, and state of the college or university:

An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

Type I. A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. You must complete Part IV, Sections A and B.

Type II. A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). You must complete Part IV, Sections A and C.

Type III functionally integrated. A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). You must complete Part IV, Sections A, D, and E.

Type III non-functionally integrated. A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). You must complete Part IV, Sections A and D, and Part V.

Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

Enter the number of supported organizations ...............................

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
(i) Name of supported organization	(ii) EIN	Yes	No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)


Total

For Paperwork Reduction Act Notice, see the Instructions for
Form 990 or 990-EZ.

Cat. No. 11285F

Schedule A (Form 990) 2022

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization failed to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") ..	39,635,190	35,740,875	48,502,473	46,522,410	43,451,535	213,852,483
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3	39,635,190	35,740,875	48,502,473	46,522,410	43,451,535	213,852,483
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) ..						483,485
6	Public support. Subtract line 5 from line 4.						213,368,998

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
7	Amounts from line 4..	39,635,190	35,740,875	48,502,473	46,522,410	43,451,535	213,852,483
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...	1,925,519	2,176,998	1,887,633	2,074,361	1,972,869	10,037,380
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)..				7,500		7,500
11	Total support. Add lines 7 through 10						223,897,363

Gross receipts from related activities, etc. (see instructions) ..................

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here ........................................ right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2022 (line 6, column (f) divided by line 11, column (f)) .........

95.300 %

Public support percentage for 2020 Schedule A, Part II, line 14 ...............

95.090 %

16a

33 1/3% support test—2022. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2021. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2022. If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............ right arrow

10%-facts-and-circumstances test—2021. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990) 2022

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose
3	Gross receipts from activities that are not an unrelated trade or business under section 513 .....
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge
6	Total. Add lines 1 through 5
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here................................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2022 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2021 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2022 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2021 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests-2022. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ....... right arrow

33 1/3% support tests—2021. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ..... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions .... right arrow

Schedule A (Form 990) 2022

Page 4

Part IV

Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, of Part I, complete Sections A and B. If you checked box 12b, of Part I, complete Sections A and C. If you checked box 12c, of Part I, complete Sections A, D, and E. If you checked box12d, of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

Yes

Are all of the organization’s supported organizations listed by name in the organization’s governing documents?
If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose,
describe the designation. If historic and continuing relationship, explain.

Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).

Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.

Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.

Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.

Was any supported organization not organized in the United States ("foreign supported organization")? If “Yes” and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.

Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If “Yes,” describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.

Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If “Yes,” explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.

Did the organization add, substitute, or remove any supported organizations during the tax year? If “Yes,” answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).

Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?

Substitutions only. Was the substitution the result of an event beyond the organization's control?

Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization’s supported organizations? If “Yes,” provide detail in Part VI.

Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If “Yes,” complete Part I of Schedule L (Form 990) .

Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? If “Yes,” complete Part I of Schedule L (Form 990).

Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If “Yes,” provide detail in Part VI.

Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If “Yes,” provide detail in Part VI.

Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If “Yes,” provide detail in Part VI.

10a

Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If “Yes,” answer line 10b below.

10a

Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).

10b

Schedule A (Form 990) 2022

Page 5

Part IV

Supporting Organizations (continued)

Yes

Has the organization accepted a gift or contribution from any of the following persons?

A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?

11a

A family member of a person described on 11a above?

11b

A 35% controlled entity of a person described on line 11a or 11b above? If “Yes” to 11a, 11b, or 11c, provide detail in Part VI.

11c

Section B. Type I Supporting Organizations

Yes

Did the officers, directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization’s directors or trustees at all times during the tax year? If “No,” describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization’s activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.

Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If “Yes,” explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.

Section C. Type II Supporting Organizations

Yes

Were a majority of the organization’s directors or trustees during the tax year also a majority of the directors or trustees of each of the organization’s supported organization(s)? If “No,” describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).

Section D. All Type III Supporting Organizations

Yes

Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization’s tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization’s governing documents in effect on the date of notification, to the extent not previously provided?

Were any of the organization’s officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).

By reason of the relationship described in line 2 above, did the organization’s supported organizations have a significant voice in the organization’s investment policies and in directing the use of the organization’s income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization’s supported organizations played in this regard.

Section E. Type III Functionally-Integrated Supporting Organizations

Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):

The organization satisfied the Activities Test. Complete line 2 below.

The organization is the parent of each of its supported organizations. Complete line 3 below.

The organization supported a governmental entity. Describe in Part VI how you supported a government entity (see instructions)

Activities Test. Answer lines 2a and 2b below.

Yes

Did substantially all of the organization’s activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.

Did the activities described on line 2a, above constitute activities that, but for the organization’s involvement, one or more of the organization’s supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization’s position that its supported organization(s) would have engaged in these activities but for the organization’s involvement.

Parent of Supported Organizations. Answer lines 3a and 3b below.

Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations?If "Yes" or "No", provide details in Part VI.

Did the organization exercise a substantial degree of direction over the policies, programs and activities of each of its supported organizations? If "Yes," describe in Part VI. the role played by the organization in this regard.

Schedule A (Form 990) 2022

Page 6

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions. All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

	Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1
2	Recoveries of prior-year distributions	2
3	Other gross income (see instructions)	3
4	Add lines 1 through 3	4
5	Depreciation and depletion	5
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6
7	Other expenses (see instructions)	7
8	Adjusted Net Income (subtract lines 5, 6 and 7 from line 4)	8

	Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):	1
a	Average monthly value of securities	1a
b	Average monthly cash balances	1b
c	Fair market value of other non-exempt-use assets	1c
d	Total (add lines 1a, 1b, and 1c)	1d
e	Discount claimed for blockage or other factors (explain in detail in Part VI):
2	Acquisition indebtedness applicable to non-exempt use assets	2
3	Subtract line 2 from line 1d	3
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5
6	Multiply line 5 by 0.035	6
7	Recoveries of prior-year distributions	7
8	Minimum Asset Amount (add line 7 to line 6)	8

	Section C - Distributable Amount		Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1
2	Enter 85% of line 1	2
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3
4	Enter greater of line 2 or line 3	4
5	Income tax imposed in prior year	5
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6

Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions)

Schedule A (Form 990) 2022

Page 7

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations(continued)

Section D - Distributions		Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes	1
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	3
4 Amounts paid to acquire exempt-use assets	4
5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI)	5
6 Other distributions (describe in Part VI). See instructions	6
7Total annual distributions. Add lines 1 through 6.	7
8 Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions	8
9 Distributable amount for 2022 from Section C, line 6	9
10 Line 8 amount divided by Line 9 amount	10

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2022	(iii) Distributable Amount for 2022
1 Distributable amount for 2022 from Section C, line 6
2 Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI). See instructions.
3 Excess distributions carryover, if any, to 2022:
a From 2017.......
b From 2018.......
c From 2019.......
d From 2020.......
e From 2021.......
fTotal of lines 3a through e
g Applied to underdistributions of prior years
h Applied to 2022 distributable amount
i Carryover from 2017 not applied (see instructions)
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.
4Distributions for 2022 from Section D, line 7:
$
a Applied to underdistributions of prior years
b Applied to 2022 distributable amount
c Remainder. Subtract lines 4a and 4b from line 4.
5 Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions.
6 Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions.
7 Excess distributions carryover to 2023. Add lines 3j and 4c.
8 Breakdown of line 7:
a Excess from 2018.....
b Excess from 2019.....
c Excess from 2020.....
d Excess from 2021.....
e Excess from 2022.....

Schedule A (Form 990) (2022)

Schedule A (Form 990) 2022

Page 8

Part VI

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Return Reference	Explanation
SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME:	SAVINGS BOND PAYOUT - 2021 AMOUNT: $ 7,500.

Schedule A (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE C
(Form 990)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527

SchCMd Bullet

Complete if the organization is described below. SchCMd Bullet

Attach to Form 990 or Form 990-EZ.
SchCMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

If the organization answered "Yes" on Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then
Round Bullet

Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
Round Bullet

Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
Round Bullet

Section 527 organizations: Complete Part I-A only.
If the organization answered "Yes" on Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then
Round Bullet

Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
Round Bullet

Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.
If the organization answered "Yes" on Form 990, Part IV, Line 5 (Proxy Tax) (see separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then
Round Bullet

Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I-A

Complete if the organization is exempt under section 501(c) or is a section 527 organization.

Provide a description of the organization’s direct and indirect political campaign activities in Part IV. See instructions for definition of “political campaign activities."

Political campaign activity expenditures. See instructions .................................................................... SchCMd Bullet

Volunteer hours for political campaign activities. See instructions ..................................................................

Part I-B

Complete if the organization is exempt under section 501(c)(3).

Enter the amount of any excise tax incurred by the organization under section 4955 ................................ SchCMd Bullet

Enter the amount of any excise tax incurred by organization managers under section 4955 ....................... SchCMd Bullet

If the organization incurred a section 4955 tax, did it file Form 4720 for this year? .........................................

Yes No

Was a correction made? ......................................................................................................................

Yes No

If "Yes," describe in Part IV.

Part I-C

Complete if the organization is exempt under section 501(c), except section 501(c)(3).

Enter the amount directly expended by the filing organization for section 527 exempt function activities ..... SchCMd Bullet

Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ............................................................................................................................ SchCMd Bullet

Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b........... SchCMd Bullet

Did the filing organization file Form 1120-POL for this year? ...................................................................

Yes No

Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing
organization made payments. For each organization listed, enter the amount paid from the filing organization’s funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.
1
2
3
4
5
6

For Paperwork Reduction Act Notice, see the instructions for Form 990.

Cat. No. 50084S

Schedule C (Form 990) 2021

Page 2

Part II-A

Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

A Check SchCMd Bullet

if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
B Check SchCMd Bullet

if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(a) Filing organization's totals	(b) Affiliated group totals
1a	Total lobbying expenditures to influence public opinion (grass roots lobbying) ......................	0
b	Total lobbying expenditures to influence a legislative body (direct lobbying) ........................	0
c	Total lobbying expenditures (add lines 1a and 1b) ............................................................	0
d	Other exempt purpose expenditures ...............................................................................	47,565,242
e	Total exempt purpose expenditures (add lines 1c and 1d) ..................................................	47,565,242
f	Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000
	If the amount on line 1e, column (a) or (b) is:The lobbying nontaxable amount is:
	Not over $500,00020% of the amount on line 1e.
	Over $500,000 but not over $1,000,000$100,000 plus 15% of the excess over $500,000.
	Over $1,000,000 but not over $1,500,000$175,000 plus 10% of the excess over $1,000,000.
	Over $1,500,000 but not over $17,000,000$225,000 plus 5% of the excess over $1,500,000.
	Over $17,000,000$1,000,000.

g	Grassroots nontaxable amount (enter 25% of line 1f) .................................................	250,000
h	Subtract line 1g from line 1a. If zero or less, enter -0-. ................................................	0
i	Subtract line 1f from line 1c. If zero or less, enter -0-. ................................................	0
j	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ...................................................................................................................		Yes No

4-Year Averaging Period Under Section 501(h) (Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the separate instructions for lines 2a through 2f.)
Lobbying Expenditures During 4-Year Averaging Period
	Calendar year (or fiscal year beginning in)	(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) Total

2a	Lobbying nontaxable amount	1,000,000	1,000,000	1,000,000	1,000,000	4,000,000

b	Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000

c	Total lobbying expenditures

d	Grassroots nontaxable amount	250,000	250,000	250,000	250,000	1,000,000

e	Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000

f	Grassroots lobbying expenditures

Schedule C (Form 990) 2021

Page 3

Part II-B

Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.

(a)

Yes|No

(b)

Amount

During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:

Volunteers? ...........................................................................................................

Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? ........

Media advertisements? ...................................................................................................

Mailings to members, legislators, or the public? .............................................................................

Publications, or published or broadcast statements? ...........................................................

Grants to other organizations for lobbying purposes? ..........................................................

Direct contact with legislators, their staffs, government officials, or a legislative body? .......................

Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means? ..................

Other activities? ...................................................................................................................

Total. Add lines 1c through 1i ....................................................................................................

Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? .....

If "Yes," enter the amount of any tax incurred under section 4912 ...........................................

If "Yes," enter the amount of any tax incurred by organization managers under section 4912 ...................

If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year? ........................

Part III-A

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Yes

Were substantially all (90% or more) dues received nondeductible by members? ...............................................

Did the organization make only in-house lobbying expenditures of $2,000 or less? ............................................

Did the organization agree to carry over lobbying and political expenditures from the prior year? .................................

Part III-B

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered “Yes."

Dues, assessments and similar amounts from members ......................................................................

Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political expenses for which the section 527(f) tax was paid).

Current year .............................................................................................................................

Carryover from last year ............................................................................................................

Total ...........................................................................................................................................

Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .

If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year? ......................................................................................................................

Taxable amount of lobbying and political expenditures. See Instructions .........................................

Part IV

Supplemental Information

Provide the descriptions required for Part l-A, line 1; Part l-B, line 4; Part l-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (see instructions), and Part ll-B, line 1. Also, complete this part for any additional information.

Return Reference	Explanation

Schedule C (Form 990) 2021

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
SchDMd Bullet

Attach to Form 990.
SchDMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate value of contributions to (during year)
3	Aggregate value of grants from (during year)
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization’s property, subject to the organization’s exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements.
Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements ......................	2a
b	Total acreage restricted by conservation easements ....................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register ...	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the
tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ............

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .............................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenue included on Form 990, Part VIII, line 1 ......................... SchDMd Bullet

(ii)

Assets included in Form 990, Part X ............................... SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under FASB ASC 958 relating to these items:

Revenue included on Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2021

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?...

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No


b	If "Yes," explain the arrangement in Part XIII and complete the following table:		Amount
c	Beginning balance .............................	1c
d	Additions during the year ............................	1d
e	Distributions during the year ..........................	1e
f	Ending balance ................................	1f

Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ...

Yes No

If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ....

Part V

Endowment Funds.
Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

		(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back

1a	Beginning of year balance ....	325,000	302,000	302,000	302,000	320,000
b	Contributions ...	14,978	13,634	14,744	14,778	14,385
c	Net investment earnings, gains, and losses	-14,978	23,000			-18,000
d	Grants or scholarships ...
e	Other expenditures for facilities and programs ...	14,978	13,634	14,744	14,778	14,385
f	Administrative expenses ....
g	End of year balance ......	310,022	325,000	302,000	302,000	302,000

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

0 %

Permanent endowment SchDMd Bullet

100.000 %

Term endowment SchDMd Bullet

0 %

The percentages on lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) Unrelated organizations .................

3a(i)

Yes

(ii) Related organizations .................

3a(ii)

If "Yes" on 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property		(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value

1a	Land .....	2,800,000	1,147,363		3,947,363
b	Buildings ....	1,629,400	5,328,141	4,057,635	2,899,906
c	Leasehold improvements
d	Equipment ....		1,946,235	694,631	1,251,604
e	Other .....		216,753	187,347	29,406
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).)..					8,128,279

Schedule D (Form 990) 2021

Page 3

Part VII

Investments - Other Securities.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives.........
(2) Closely-held equity interests........
(3)Other
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)

Part VIII

Investments - Program Related. Complete if the organization answered 'Yes' on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description				(b) Book value

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........

Part X

Other Liabilities.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1.(a) Description of liability	(b) Book value
(1) Federal income taxes
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)	715,557
2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII

Schedule D (Form 990) 2021

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......			1	67,833,289
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains (losses) on investments ....	2a	-2,139,406
b	Donated services and use of facilities .........	2b	25,308,680
c	Recoveries of prior year grants ...........	2c	1,028,552
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d .....................			2e	24,197,826
3	Subtract line 2e from line 1..................			3	43,635,463
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a	327,036
b	Other (Describe in Part XIII.) ...........	4b	-68,702
c	Add lines 4a and 4b....................			4c	258,334
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......			5	43,893,797

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........			1	73,291,396
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities .........	2a	25,308,680
b	Prior year adjustments ............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d	26,923
e	Add lines 2a through 2d....................			2e	25,335,603
3	Subtract line 2e from line 1...................			3	47,955,793
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a	327,036
b	Other (Describe in Part XIII.) ............	4b	225,385
c	Add lines 4a and 4b.....................			4c	552,421
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......			5	48,508,214

Part XIII

Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference	Explanation
PART V, LINE 4:	THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR THE ALZHEIMER'S DISEASE RESEARCH PROGRAM, ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT INCOME, AND ARE RELEASED AS SPENT.
PART X, LINE 2:	BRIGHTFOCUS PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2023, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS.
PART XI, LINE 4B - OTHER ADJUSTMENTS:	DEPRECIATION OF RENTAL PROPERTY -41,779. FUNDRAISING EVENT EXPENSES -26,923.
PART XII, LINE 2D - OTHER ADJUSTMENTS:	FUNDRAISING EVENT EXPENSES 26,923.
PART XII, LINE 4B - OTHER ADJUSTMENTS:	DEPRECIATION ON RENTAL PROPERTY -41,779. CHANGE IN PRESENT VALUE OF GRANTS 267,164.

Schedule D (Form 990) 2021

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE F(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990, Part IV, line 14b, 15, or 16. Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I

General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

For grantmakers. Does the organization maintain records to substantiate the amount of its grants and

other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used

to award the grants or assistance? . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.

Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region		(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(f) Total expenditures for and investments in the region
	EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING	334,938
	EUROPE	0	0	GRANTMAKING	1,765,924
	MIDDLE EAST AND NORTH AFRICA	0	0	GRANTMAKING	300,000
	NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES	0	0	GRANTMAKING	200,000













3a	Sub-total ....	0	0		2,600,862
b	Total from continuation sheets to Part I ...	0	0		0
c	Totals (add lines 3a and 3b)	0	0		2,600,862

For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2022

Schedule F (Form 990) 2022

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance
EUROPE	ALZHEIMER'S DISEASE RESEARCH BY L. CHAVEZ GUTIERREZ, PHD, ENTITLED: (A2023005S)	300,000	WIRE TRANSFER	0
EUROPE	ALZHEIMER'S DISEASE RESEARCH BY MARTA CASQUERO-VEIGA, PHD, ENTITLED: (A2023012F)	200,000	WIRE TRANSFER	0
EUROPE	ALZHEIMER'S DISEASE RESEARCH BY QI WANG, PHD, ENTITLED: (A2023018F)	200,000	WIRE TRANSFER	0
MIDDLE EAST	ALZHEIMER'S DISEASE RESEARCH BY ARIEL GILAD, PHD, ENTITLED: (A2023024S)	300,000	WIRE TRANSFER	0
EUROPE	ALZHEIMER'S DISEASE RESEARCH BY LOUISE VAN DER WEERD, PHD, ENTITLED: (A2023026S)	299,354	WIRE TRANSFER	0
EUROPE	ALZHEIMER'S DISEASE RESEARCH CONFERENCE SUPPORT	99,353	WIRE TRANSFER	0
EUROPE	TRAVEL GRANTS FOR CONFERENCE ATTENDANCE	10,000	WIRE TRANSFER	0
EUROPE	ALZHEIMER'S DISEASE RESEARCH BY DR. GAELLE CHETELAT, ENTITLED: (CA2021013)	25,000	WIRE TRANSFER	0
EUROPE	NATIONAL GLAUCOMA RESEARCH BY KAREN PEYNSHAERT, PHD, ENTITLED: (G2023002F)	150,000	WIRE TRANSFER	0
NORTH AMERICA	NATIONAL GLAUCOMA RESEARCH BY ADRIANA DI POLO, PHD, ENTITLED: (G2023005S)	200,000	WIRE TRANSFER	0
EUROPE	NATIONAL GLAUCOMA RESEARCH BY SILVIA MARINELLI, PHD, ENTITLED: (G2023006S)	200,000	WIRE TRANSFER	0
EUROPE	NATIONAL GLAUCOMA RESEARCH BY DARRYL OVERBY, PHD, ENTITLED: (G2023011S)	184,242	WIRE TRANSFER	0
EUROPE	NATIONAL GLAUCOMA RESEARCH BY DARRYL OVERBY, PHD, ENTITLED: (CG2020003)	97,975	WIRE TRANSFER	0
EAST ASIA & PACIFIC	MACULAR DEGENERATION RESEARCH BY MATTHEW RUTAR, PHD, ENTITLED: (M2023009N)	334,938	WIRE TRANSFER	0

2	Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .......	13
3	Enter total number of other organizations or entities .......................	0

Schedule F (Form 990) 2022

Schedule F (Form 990) 2022Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of noncash assistance	(g) Description of noncash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2022

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2022

Page 5

Part V

Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

ReturnReference	Explanation
PART I, LINE 2:	BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS. AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT. BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.
PART I, LINE 3:	BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.
PART III ACCOUNTING METHOD:
PART II, LINE 1:	BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

Schedule F (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE G (Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding
Fundraising or Gaming Activities

Complete if the organization answered "Yes" on Form 990, Part IV, lines 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a. right arrow

Attach to Form 990 or Form 990-EZ.
right arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I

Fundraising Activities.Complete if the organization answered "Yes" on Form 990, Part IV, line 17.

Form 990-EZ filers are not required to complete this part.

Indicate whether the organization raised funds through any of the following activities. Check all that apply.

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and email solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations

Did the organization have a written or oral agreement with any individual (including officers, directors, trustees

or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

YesNo

If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)		(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
			Yes	No
	RKD GROUP 35 PARKWOOD DRIVE STE 160 HOPKINTON, MA01748	FUNDRAISING AND COMMUNICATIONS CONSULTANT		No	30,452,088	499,942	29,952,146
	ALLEGIANCE GROUP 2300 CLARENDON BLVD STE 925 ARLINGTON, VA22201	FUNDRAISING AND COMMUNICATIONS CONSULTANT		No	2,368,623	452,839	1,915,784








Total . . . . . . . . . . . . . . . . . . . .					32,820,711	952,781	31,867,930

List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

AK, AL, AR, AZ, CA, CO, CT, DC, FL, GA, HI, IL, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, ND, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WI, WV

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 50083H

Schedule G (Form 990) 2022

Page 2

Part II

Fundraising Events. Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

		(a) Event #1 AN EVENING OF BRIGHTFOCUS (event type)	(d) Total events (add col. (a) through col. (c))
1	Gross receipts . . . . .	306,298	306,298
2	Less: Contributions . . . .	242,498	242,498
3	Gross income (line 1 minus line 2) . . . . . .	63,800	63,800

4	Cash prizes . . . . .
5	Noncash prizes . . . .
6	Rent/facility costs . . . .	44,401	44,401
7	Food and beverages . . .	129,808	129,808
8	Entertainment . . . .	71,034	71,034
9	Other direct expenses . . .	127,811	127,811
10	Direct expense summary. Add lines 4 through 9 in column (d) . . . . . . . . . .		373,054
11	Net income summary. Subtract line 10 from line 3, column (d). . . . . . . . . .		-309,254

Part III

Gaming. Complete if the organization answered "Yes" on Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

		(a) Bingo	(b) Pull tabs/Instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col.(a) through col.(c))
1	Gross revenue . . . . .

2	Cash prizes . . . . .
3	Noncash prizes . . . .
4	Rent/facility costs . . . .
5	Other direct expenses . . .

Volunteer labor . . . .

	Yes %
	No

	Yes %
	No

	Yes %
	No

Direct expense summary. Add lines 2 through 5 in column (d) . . . . . . . . . . right arrow

Net gaming income summary. Subtract line 7 from line 1, column (d). . . . . . . . . right arrow

Enter the state(s) in which the organization conducts gaming activities:

Is the organization licensed to conduct gaming activities in each of these states? . . . . . . . .

YesNo

If "No," explain:

10a

Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? . . .

YesNo

If "Yes," explain:

Schedule G (Form 990) 2022

Page 3

Does the organization conduct gaming activities with nonmembers? . . . . . . . . . . .

YesNo

Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity

formed to administer charitable gaming? . . . . . . . . . . . . . . . . .

YesNo

Indicate the percentage of gaming activity conducted in:

The organization's facility . . . . . . . . . . . . . . . . . .

13a

An outside facility . . . . . . . . . . . . . . . . . . . .

13b

Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name

Address

15a

Does the organization have a contract with a third party from whom the organization receives gaming

revenue? . . . . . . . . . . . . . . . . . . . . . . . .

YesNo

If "Yes," enter the amount of gaming revenue received by the organization right arrow

$ and the

amount of gaming revenue retained by the third party right arrow

$ .

If "Yes," enter name and address of the third party:

Name

Address

Gaming manager information:

Name

Gaming manager compensation right arrow

Description of services provided right arrow

Director/officer Employee Independent contractor

Mandatory distributions:

Is the organization required under state law to make charitable distributions from the gaming proceeds to

retain the state gaming license? . . . . . . . . . . . . . . . . . . .

YesNo

Enter the amount of distributions required under state law distributed to other exempt organizations or spent

in the organization's own exempt activities during the tax year right arrow

Part IV

Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

Return Reference	Explanation
SCHEDULE G, PART I, LINE 2B, COLUMN (V)	IN THE CONTRACT WITH RKD GROUP, THE MANAGEMENT FEES ARE FIXED AMOUNTS PER MONTH FOR IN-SCOPE SERVICES THAT TOTALS $1,128,624 PER YEAR OF WHICH $628,682 HAS BEEN ALLOCATED UNDER PART XI, LINE 11(G) TO PROGRAM AND MANAGEMENT AND ARE NOT CONSIDERED TO BE THE PROFESSIONAL FUNDRAISING CONSULTANT FEE.

Schedule G (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

Note: To capture the full content of this document, please select landscape mode (11" x 8.5") when printing.

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," on Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990.
lBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ........................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient

that received more than $5,000. Part II can be duplicated if additional space is needed.

(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(h) Purpose of grant or assistance
(1) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02145	04-2697983	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY ZAHRA SHIRZADI, PHD, ENTITLED: (A2023001F)
(2) BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA MS BCM 310 HOUSTON,TX77030	74-1613878	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY DAHEUN CHUNG, PHD, ENTITLED: (A2023002F)
(3) NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE 750 N LAKE SHORE DRIVE RUBLOFF 7TH FLOOR CHICAGO,IL60611	36-2167817	501(C)(3)	300,000	ALZHEIMER'S DISEASE RESEARCH BY DAVID GATE, PHD, ENTITLED: (A2023003S)
(4) JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE 733 NORTH BROADWAY SUITE 117 BROADWAY RESEARCH BUILDING BALTIMORE,MD21205	52-0595110	501(C)(3)	296,426	ALZHEIMER'S DISEASE RESEARCH BY MEAGHAN MORRIS, MD, PHD, ENTITLED: (A2023004S)
(5) CORNELL UNIVERSITY 373 PINE TREE ROAD ITHACA,NY14850	15-0532082	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY MATTHEW ISAACSON, PHD, ENTITLED: (A2023006F)
(6) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02145	04-2697983	501(C)(3)	199,600	ALZHEIMER'S DISEASE RESEARCH BY JOOST RIPHAGEN, MD, PHD, ENTITLED: (A2023007F)
(7) WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVE NEW YORK,NY10065	13-1623978	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY TILL ZIMMER, PHD, ENTITLED: (A2023008F)
(8) UNIVERSITY OF SOUTH FLORIDA 3702 SPECTRUM BLVD SUITE 165 TAMPA,FL33612	59-3102112	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY ARI SUDWARTS, PHD, ENTITLED: (A2023009F)
(9) UNIVERSITY OF CALIFORNIA LOS ANGELES 10889 WILSHIRE BOULEVARD SUITE LOS ANGELES,CA90095	95-6006143	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY DAVID BOYER, PHD, ENTITLED: (A2023010F)
(10) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02145	04-2697983	501(C)(3)	300,000	ALZHEIMER'S DISEASE RESEARCH BY JINGYUAN CHEN, PHD, ENTITLED: (A2023011S)
(11) NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE 750 N LAKE SHORE DRIVE RUBLOFF 7TH FLOOR CHICAGO,IL60611	36-2167817	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY ARUN UPADHYAY, PHD, ENTITLED: (A2023013F)
(12) WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVE NEW YORK,NY10065	13-1623978	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY SUNG JI AHN, PHD, ENTITLED: (A2023014F)
(13) JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE 733 NORTH BROADWAY SUITE 117 BROADWAY RESEARCH BUILDING BALTIMORE,MD21205	52-0595110	501(C)(3)	300,000	ALZHEIMER'S DISEASE RESEARCH BY ALYSSA COYNE, PHD, ENTITLED: (A2023015S)
(14) UNIVERSITY OF SOUTHERN CALIFORNIA 3720 S FLOWER STREET 3RD FLOOR LOS ANGELES,CA90089	95-1642394	501(C)(3)	299,141	ALZHEIMER'S DISEASE RESEARCH BY PAUL SEIDLER, PHD, ENTITLED: (A2023016S)
(15) SHRINERS HOSPITALS FOR CHILDREN - NORTHERN CALIFORNIA 2425 STOCKTON BLVD SACRAMENTO,CA95817	36-2193608	501(C)(3)	300,000	ALZHEIMER'S DISEASE RESEARCH BY OLGA CHECHNEVA, PHD, ENTITLED: (A2023017S)
(16) UNIVERSITY OF CALIFORNIA SAN FRANCISCO OFFICE OF SPONSORED RESEARCH 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO,CA94143	94-6036493	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY HENRY PAN, PHD, ENTITLED: (A2023019F)
(17) UNIVERSITY OF KENTUCKY 500 SOUTH LIMESTONE LEXINGTON,KY40526	61-6033693	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY KATE FOLEY, PHD, ENTITLED: (A2023020F)
(18) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON,MA02145	04-2697983	501(C)(3)	200,000	ALZHEIMER'S DISEASE RESEARCH BY MARIA VIRTUDES SANCHEZ MICO, PHD, ENTITLED: (A2023021F)
(19) YALE UNIVERSITY 150 MUNSON STREET PO BOX 208327 NEW HAVEN,CT06520	06-0646973	501(C)(3)	300,000	ALZHEIMER'S DISEASE RESEARCH BY CARLA ROTHLIN, PHD, ENTITLED: (A2023022S)
(20) UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE DEPT 0934 LA JOLLA,CA92093	95-6006144	501(C)(3)	300,000	ALZHEIMER'S DISEASE RESEARCH BY SUBHOJIT ROY, MD, PHD, ENTITLED: (A2023023S)
(21) UNIVERSITY OF KENTUCKY 500 SOUTH LIMESTONE LEXINGTON,KY40526	61-6033693	501(C)(3)	300,000	ALZHEIMER'S DISEASE RESEARCH BY DANIEL C. LEE, PHD, ENTITLED: (A2023025S)
(22) MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD ROOM 110 JACKSONVILLE,FL32224	59-3337028	501(C)(3)	235,163	ALZHEIMER'S DISEASE RESEARCH ENTITLED: (CA2021010)
(23) LUMIND IDSC 20 MALL ROAD SUITE 200 BURLINGTON,VT01803	37-1483975	501(C)(3)	65,000	ALZHEIMER'S DISEASE RESEARCH RELATED TO DOWN SYNDROME
(24) INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION 1001 MAYPORT RD ATLANTIC BEACH,FL32233	86-2907045	501(C)(3)	9,000	ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE
(25) INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION 1001 MAYPORT RD ATLANTIC BEACH,FL32233	86-2907045	501(C)(3)	115,000	ALZHEIMER'S DISEASE RESEARCH ENTITLED: (CA2021011)
(26) UNIVERSITY OF CALIFORNIA IRVINE 320 QURESHEY RESEARCH LAB IRVINE,CA92697	95-2226406	501(C)(3)	10,000	ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE
(27) FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH 11400 ROCKVILLE PIKE SUITE 600 NORTH BETHESDA,MD20852	52-1986675	501(C)(3)	100,000	ALZHEIMER'S DISEASE RESEARCH BY SJOERD FINNEMA, PHD, ENTITLED: (CA2021012)
(28) UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL BUILDING13001 E 17TH PLACE AURORA,CO80045	84-6000555	501(C)(3)	87,500	ALZHEIMER'S DISEASE RESEARCH BY LOTTA GRANHOLM, PHD, ENTITLED: (CA2018010)
(29) UNIVERSITY OF SOUTHERN CALIFORNIA 3720 S FLOWER STREET 3RD FLOOR LOS ANGELES,CA90089	95-1642394	501(C)(3)	600,000	ALZHEIMER'S DISEASE RESEARCH BY JINKOOK LEE, PHD, ENTITLED: (CA2023001)
(30) UNIVERSITY OF CALIFORNIA BERKELEY 1608 FOURTH STREET SUITE 220 BERKELEY,CA94710	94-6002123	501(C)(3)	150,000	NATIONAL GLAUCOMA RESEARCH BY SHUBHAM MAURYA, PHD, ENTITLED: (G2023001F)
(31) UNIVERSITY OF WISCONSIN-MADISON 21 NORTH PARK STREET SUITE 6301 MADISON,WI53715	39-6006492	501(C)(3)	150,000	NATIONAL GLAUCOMA RESEARCH BY KAZUYA OIKAWA, PHD, BVSC, ENTITLED: (G2023003F)
(32) UNIVERSITY OF CALIFORNIA BERKELEY 1608 FOURTH STREET SUITE 220 BERKELEY,CA94710	94-6002123	501(C)(3)	199,999	NATIONAL GLAUCOMA RESEARCH BY KARTHIK SHEKHAR, PHD, ENTITLED: (G2023004S)
(33) GEORGIA TECH RESEARCH CORPORATION 926 DALNEY STREET NW ATLANTA,GA30332	58-0603146	501(C)(3)	200,000	NATIONAL GLAUCOMA RESEARCH BY MARK PRAUSNITZ, PHD, ENTITLED: (G2023007S)
(34) DUKE UNIVERSITY SCHOOL OF MEDICINE 2200 WEST MAIN STREET SUITE 820 DURHAM,NC27705	56-0532129	501(C)(3)	200,000	NATIONAL GLAUCOMA RESEARCH BY RUPALATHA MADDALA, PHD, ENTITLED: (G2023008S)
(35) INDIANA UNIVERSITY INDIANAPOLIS 509 E 3RD STREET BLOOMINGTON,IN47401	35-6001673	501(C)(3)	200,000	NATIONAL GLAUCOMA RESEARCH BY WEIMING MAO, PHD, ENTITLED: (G2023009S)
(36) JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE 733 NORTH BROADWAY SUITE 117 BROADWAY RESEARCH BUILDING BALTIMORE,MD21205	52-0595110	501(C)(3)	200,000	NATIONAL GLAUCOMA RESEARCH BY JITHIN YOHANNAN, MD, ENTITLED: (G2023010S)
(37) INTERNATIONAL SOCIETY FOR EYE RESEARCH 655 BEACH STREET SAN FRANCISCO,CA94109	51-0171667	501(C)(3)	8,000	TRAVEL GRANTS FOR CONFERENCE ATTENDANCE
(38) GEORGIA INSTITUTE OF TECHNOLOGY FERST DRIVE ROOM 230 ATLANTA,GA30332	58-6002023	501(C)(3)	85,561	NATIONAL GLAUCOMA RESEARCH BY C. ROSS ETHIER, PHD, ENTITLED: (CG2020001)
(39) DUKE UNIVERSITY 2200 WEST MAIN STREET SUITE 820 DURHAM,NC27705	56-0532129	501(C)(3)	52,324	NATIONAL GLAUCOMA RESEARCH BY W. DANIEL STAMER, PHD, ENTITLED: (CG2020002)
(40) COLUMBIA UNIVERSITY 535 W 116TH STREET NEW YORK,NY10027	13-5598093	501(C)(3)	166,666	NATIONAL GLAUCOMA RESEARCH BY SIMON JOHN, PHD, ENTITLED: (CG2020004)
(41) STANFORD UNIVERSITY 2452 WATSON CT PALO ALTO,CA94305	94-1156365	501(C)(3)	74,023	NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG, PHD, ENTITLED: (CG2022001)
(42) THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR,ME04609	01-0211513	501(C)(3)	200,000	MACULAR DEGENERATION RESEARCH BY NAVDEEP GOGNA, PHD, ENTITLED: (M2023001F)
(43) UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET FRANKLIN BUILDING 5TH FLOOR PHILADELPHIA,PA19104	23-1352685	501(C)(3)	200,000	MACULAR DEGENERATION RESEARCH BY CATHARINA GRUBAUGH, PHD, ENTITLED: (M2023002F)
(44) UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MAIL CODE 0041 LA JOLLA,CA92093	95-6006144	501(C)(3)	200,000	MACULAR DEGENERATION RESEARCH BY JACLYN SWAN, PHD, ENTITLED: (M2023003F)
(45) UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE BOX 359472 SEATTLE,WA98195	91-6001537	501(C)(3)	200,000	MACULAR DEGENERATION RESEARCH BY RAYNE LIM, PHD, ENTITLED: (M2023004F)
(46) UNIVERSITY OF CALIFORNIA SAN FRANCISCO OFFICE OF SPONSORED RESEARCH 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO,CA94143	94-6036493	501(C)(3)	200,000	MACULAR DEGENERATION RESEARCH BY SANGEETHA KANDOI, PHD, ENTITLED: (M2023005F)
(47) WASHINGTON UNIVERSITY IN STLOUIS CAMPUS BOX 1054 ONE BROOKINGS DR ST LOUIS,MO63130	43-0653611	501(C)(3)	200,000	MACULAR DEGENERATION RESEARCH BY JAMES WALSH, MD, PHD, ENTITLED: (M2023006F)
(48) THE UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS 2 GILMORE HALL IOWA CITY,IA52242	42-6004813	501(C)(3)	200,000	MACULAR DEGENERATION RESEARCH BY NARENDRA PANDALA, PHD, ENTITLED: (M2023007F)
(49) OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD MAIL CODE L106OPAM PORTLAND,OR97239	93-1176109	501(C)(3)	598,868	MACULAR DEGENERATION RESEARCH BY YALI JIA, PHD, ENTITLED: (M2023008I)
(50) UNIVERSITY OF WISCONSIN-MADISON 21 NORTH PARK STREET SUITE 6301 MADISON,WI53715	39-6006492	501(C)(3)	450,000	MACULAR DEGENERATION RESEARCH BY FREYA MOWAT, PHD, ENTITLED: (M2023010N)
(51) THE UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS 2 GILMORE HALL IOWA CITY,IA52242	42-6004813	501(C)(3)	450,000	MACULAR DEGENERATION RESEARCH BY KELLY MULFAUL, PHD, ENTITLED: (M2023011N)
(52) THE UNIVERSITY OF TEXAS AT AUSTIN 3925 WEST BRAKER LN SUITE 3340 AUSTIN,TX78759	74-6000203	501(C)(3)	436,312	MACULAR DEGENERATION RESEARCH BY LYNDSAY LEACH, PHD, ENTITLED: (M2023012N)
(53) YALE UNIVERSITY 150 MUNSON STREET PO BOX 208327 NEW HAVEN,CT06520	06-0646973	501(C)(3)	168,917	MACULAR DEGENERATION RESEARCH BY ABDELILAH MAJDOUBI, PHD, ENTITLED: (M2023013F)
(54) UNIVERSITY OF CALIFORNIA IRVINE 120 THEORY STREET 200 IRVINE,CA92617	95-2226406	501(C)(3)	25,000	MACULAR DEGENERATION RESEARCH BY DOROTA SKOWRONSKA-KRAWCZYK, PHD, ENTITLED: (M2020271)
(55) HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION 1201 11TH AVE SOUTH SUITE 300 BIRMINGHAM,AL35205	63-0983733	501(C)(3)	75,000	2022 HELEN KELLER PRIZE FOR VISION RESEARCH PARTNERSHIP
(56) HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION 1201 11TH AVE SOUTH SUITE 300 BIRMINGHAM,AL35205	63-0983733	501(C)(3)	75,000	2022 CONFERENCE SUPPORT
(57) ARVO FOUNDATION FOR EYE RESEARCH 1801 ROCKVILLE PIKE SUITE 400 ROCKVILLE,MD20852	52-2322462	501(C)(3)	10,000	2022 EYEFIND RESEARCH GRANT SPONSORSHIP
(58) ARVO FOUNDATION FOR EYE RESEARCH 1801 ROCKVILLE PIKE SUITE 400 ROCKVILLE,MD20852	52-2322462	501(C)(3)	15,240	2022 TRAVEL GRANTS FOR CONFERENCE ATTENDEES

Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................. Bullet Image

Enter total number of other organizations listed in the line 1 table ........................ . Bullet Image

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2022

Page 2

Part III

Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of noncash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

(1) CONFERENCE TRAVEL	6	6,000
(1)
(2)
(3)
(4)
(5)
(6)
(7)

Part IV

Supplemental Information. Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

Return Reference

Explanation

PART I, LINE 2:

BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS. AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT. BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

Schedule I (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
SchJMediumBullet

Attach to Form 990.
SchJMediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed on Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes on Line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain .....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked on Line 1a? ....

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? .............

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ....................

Any related organization? .......................

If "Yes," on line 5a or 5b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ..................

Any related organization? ......................

If "Yes," on line 6a or 6b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Yes

Were any amounts reported on Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III ..........................

If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2022

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2, 1099-MISC compensation, and/or 1099-NEC			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
1STACY PAGOS HALLER PRESIDENT/CEO	(i) (ii)	394,212 ------------- 0	45,000 ------------- 0	1,584 ------------- 0	27,450 ------------- 0	24,778 ------------- 0	493,024 ------------- 0	0 ------------- 0
2NANCY LYNN SR. VP STRATEGIC PARTNERSHIPS	(i) (ii)	248,810 ------------- 0	0 ------------- 0	1,584 ------------- 0	23,409 ------------- 0	31,894 ------------- 0	305,697 ------------- 0	0 ------------- 0
3R BRIAN ELDERTON SR. VP, DEVELOPMENT	(i) (ii)	241,463 ------------- 0	0 ------------- 0	1,715 ------------- 0	22,353 ------------- 0	24,387 ------------- 0	289,918 ------------- 0	0 ------------- 0
4DAVID F MARKS CPA CMA VP, FINANCE & ADMINISTRATION	(i) (ii)	165,347 ------------- 0	0 ------------- 0	1,584 ------------- 0	16,082 ------------- 0	41,994 ------------- 0	225,007 ------------- 0	0 ------------- 0
5DIANE BOVENKAMP PHD VP, SCIENTIFIC AFFAIRS	(i) (ii)	181,530 ------------- 0	0 ------------- 0	552 ------------- 0	16,338 ------------- 0	4,840 ------------- 0	203,260 ------------- 0	0 ------------- 0
6AYO ABRAHAM CPA CGMA CONTROLLER	(i) (ii)	140,493 ------------- 0	0 ------------- 0	1,032 ------------- 0	8,448 ------------- 0	6,796 ------------- 0	156,769 ------------- 0	0 ------------- 0
7LISA MORGAN DIRECTOR OF ANNUAL GIVING	(i) (ii)	119,467 ------------- 0	0 ------------- 0	552 ------------- 0	11,363 ------------- 0	21,828 ------------- 0	153,210 ------------- 0	0 ------------- 0
8SHARYN ROSSI PHD DIR OF SCIENT. PROGRAMS, NEUROSCIENCE	(i) (ii)	117,281 ------------- 0	0 ------------- 0	240 ------------- 0	4,394 ------------- 0	30,261 ------------- 0	152,176 ------------- 0	0 ------------- 0

Schedule J (Form 990) 2022

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Return Reference

Explanation

PART I, LINE 7

AS THE PRESIDENT/CEO'S BONUS WAS NOT A FIXED PAYMENT SPECIFIED IN HER EMPLOYMENT CONTRACT, THIS ITEM HAS BEEN ANSWERED 'YES' IN ACCORDANCE WITH THE INTERNAL REVENUE SERVICE INSTRUCTIONS. HOWEVER, IT SHOULD BE NOTED THAT HER BONUS WAS A NON-FIXED PAYMENT BASED ON BRIGHTFOCUS' INTERNAL PROCEDURES. THE BOARD OF DIRECTORS CONSIDERS THE AWARD OF A DISCRETIONARY BONUS EACH YEAR. THE DETERMINATION OF THE BONUS COMPENSATION IS CAPPED AS SPECIFIED IN HER EMPLOYMENT CONTRACT, AND IF NOT WARRANTED WILL NOT BE AWARDED AT ALL. THE DETERMINATION IS MADE BY THE FULL BOARD UPON RECOMMENDATION OF ITS EXECUTIVE COMMITTEE THAT IS RESPONSIBLE FOR THE REVIEW OF PRESIDENT/CEO COMPENSATION. THE COMMITTEE CONSIDERS A SET OF GOALS FOR THE PRESIDENT/CEO'S PERFORMANCE DEVELOPED AT THE BEGINNING OF THE YEAR IN CONSULTATION WITH THE PRESIDENT/CEO. EACH GOAL IS EVALUATED AT THE END OF THE FISCAL YEAR TO DETERMINE WHETHER THE GOAL HAS BEEN MET OR EXCEEDED. THE BONUS IS AWARDED BASED ON A DETAILED REVIEW BY THE BOARD OF DIRECTORS OF WHETHER EACH GOAL HAS BEEN MET OR EXCEEDED.

Schedule J (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.
Right pointing arrow large image

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	21	468,968	FMV
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( )
26 Other ( )
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? ...................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

If "Yes," describe in Part II.

If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2022)

Page 2

Part IISupplemental Information. Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Return Reference	Explanation
PART I, COLUMN (B):	BRIGHTFOCUS REPORTS THE NUMBER OF CONTRIBUTIONS IN PART I, COLUMN (B).

Schedule M (Form 990) (2022)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Return Reference	Explanation
FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:	BRIGHTFOCUS FUNDS EXCEPTIONAL SCIENTIFIC RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. OUR VISION IS: A WORLD FREE FROM DISEASES OF MIND AND SIGHT. COLLECTIVELY, 300 MILLION PEOPLE WORLDWIDE SUFFER FROM THESE DISEASES. BRIGHTFOCUS HAS A PROVEN TRACK RECORD OF SUPPORTING THE MOST INNOVATIVE, EARLY-STAGE RESEARCH SEEKING TO FOSTER A BETTER UNDERSTANDING OF, TREATMENTS FOR, AND ULTIMATELY, A CURE FOR, THESE AGE-RELATED DISEASES WITH NO CURE. SINCE 1973, BRIGHTFOCUS HAS AWARDED MORE THAN $287 MILLION IN RESEARCH GRANTS TO THOUSANDS OF SCIENTISTS AROUND THE WORLD. OUR RESEARCH FUNDING HAS LED TO MAJOR CONTRIBUTIONS TO UNDERSTANDING THESE DISEASES AND SUPPORT FOR SCIENTISTS WHO HAVE RECEIVED PRESTIGIOUS AWARDS, INCLUDING TWO NOBEL PRIZES. AN INDICATOR OF OUR ABILITY TO PUSH NEW BOUNDARIES OF KNOWLEDGE IS THAT BRIGHTFOCUS-SUPPORTED RESEARCH WAS RECENTLY FOUND TO HAVE HAD 10 TIMES THE IMPACT ON DRIVING FUTURE SCIENCE THAN WORK SUPPORTED BY MANY OTHER ORGANIZATIONS. THE WORLD-CLASS RESEARCH IDENTIFIED AND SUPPORTED BY BRIGHTFOCUS IS ON THE CUTTING EDGE OF THE FIGHT TO SAVE MIND AND SIGHT. OUR FUNDING ACTS AS A CATALYST IN EARLY-STAGE RESEARCH, AND BRIGHTFOCUS RESEARCH PROGRAMS ARE DESIGNED TO PROVIDE INITIAL FUNDING FOR HIGHLY INNOVATIVE EXPERIMENTAL IDEAS. DUE TO THE STRUCTURED GRANT REVIEW AND APPROVAL PROCESS, THE RESEARCH IMPACT OF BRIGHTFOCUS IS VERY HIGH. MOST RECIPIENTS OF BRIGHTFOCUS FUNDING GO ON TO RECEIVE FUTURE GRANTS FROM OTHER SOURCES THAT ARE UP TO 10 TIMES LARGER THAN THE ORIGINAL BRIGHTFOCUS AWARD. THIS HIGH RETURN ON BRIGHTFOCUS INVESTMENT SPEAKS TO OUR ABILITY TO IDENTIFY PROMISING RESEARCH IN ITS EARLIEST STAGES AND SPAWN FUTURE SCIENTIFIC DISCOVERIES. IT IS OUR FIRM BELIEF THAT HAVING THE COURAGE TO INVEST IN INNOVATIVE IDEAS WILL LEAD TO REVOLUTIONARY APPROACHES AND LIFE-SAVING BREAKTHROUGHS. ALONG WITH FUNDING CUTTING-EDGE RESEARCH TO FIND CURES FOR SOME OF THE WORLD'S COSTLIEST DISEASES, BRIGHTFOCUS ALSO PROVIDES FREE EDUCATIONAL MATERIALS AND SUPPORT TO HUNDREDS OF THOUSANDS OF THOSE IMPACTED BY THESE DISEASES NATIONWIDE. WE ROOT THESE EDUCATIONAL MATERIALS IN THE LATEST RESEARCH FINDINGS (VIEW OUR RESEARCH MILESTONES ON BRIGHTFOCUSBOLD.ORG.) BRIGHTFOCUS ALSO INCREASES PUBLIC AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND COMMUNICATES WITH THOUGHT LEADERS AND ELECTED OFFICIALS ABOUT THE IMPORTANCE OF SCIENTIFIC RESEARCH IN THESE AREAS. BRIGHTFOCUS' AWARD-WINNING PUBLIC SERVICE ANNOUNCEMENTS (PSAS) HAVE APPEARED ON TELEVISION, RADIO, AND IN PRINT THROUGHOUT THE NATION. THE IMPACT OF ALZHEIMER'S, MAKE A PLAN TODAY: GET YOUR EYES CHECKED, AND NOW IS THE MOMENT TO STOP ALZHEIMER'S DISEASE POWERFULLY SEEKS TO RAISE AWARENESS AND EARLY DETECTION, AND SIMILAR MESSAGES HAVE BEEN DELIVERED THROUGH DONATED PRINT PSA SPACE IN AIRPORTS AND TRAIN STATIONS, AS WELL AS AT PHARMACIES, SUPERMARKETS AND DIGITALLY. IN FISCAL YEAR 2023, THESE PSA MESSAGES GENERATED $25,308,680 IN DONATED MEDIA SERVICES AND GARNERED OVER 532 MILLION IMPRESSIONS. WE CONTINUE TO INCREASE OUR PRINT PUBLICATIONS, MANY IN SPANISH, THAT PROVIDE HELPFUL INFORMATION TO PATIENTS AND CAREGIVERS, AND REGULARLY UNVEIL NEW VIDEO AND AUDIO RESOURCES IN CONJUNCTION WITH ALLIES IN THE MEDICAL AND SCIENTIFIC COMMUNITIES. PARTNERING WITH SEVERAL HIGH-PROFILE PUBLIC AND PRIVATE ORGANIZATIONS, BRIGHTFOCUS IS HELPING TO BETTER EDUCATE THE PUBLIC ON THE LATEST RESEARCH DEVELOPMENTS PERTAINING TO ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AS WELL AS THE IMPORTANCE OF EQUITABLE PARTICIPATION IN CLINICAL RESEARCH TO ACCELERATE THE PATH TO CURES FOR NEURODEGENERATIVE DISEASES. SPECIFICALLY, BRIGHTFOCUS IS PRODUCING AND DISSEMINATING FREE PROGRAMS INCLUDING: - BRIGHTFOCUS CHATS, SINCE 2014, THESE AUDIO DISCUSSIONS HAVE BROUGHT TOGETHER PATIENTS AND CAREGIVERS FOR INTERACTIVE MONTHLY TELEPHONE FORUMS TO LEARN FROM AND ASK QUESTIONS OF LEADING VISION DISEASE EXPERTS. THE CHATS ARE ARCHIVED ON OUR WEBSITE, WITH AUDIO AND PRINT TRANSCRIPTS AVAILABLE IN SEVERAL ACCESSIBLE FORMATS ONLINE, INCLUDING AS PODCASTS ON SPOTIFY AND APPLE ITUNES. - ZOOM IN ON DEMENTIA AND ALZHEIMER'S, A MONTHLY VIRTUAL DISCUSSION OPEN TO THE PUBLIC FEATURING TOPIC EXPERTS. - BRAIN INFO LIVE, A SUSTAINED, EPISODIC VIRTUAL EDUCATION SERIES TAILORED TO DIVERSE COMMUNITIES ACROSS THE US PRODUCED IN ENGLISH, SPANISH, AND HAITIAN CREOLE. BRIGHTFOCUS IS A PRESENTING PARTNER OF AN UPCOMING DOCUMENTARY, REMEMBERING GENE WILDER, AS WELL AS A DOCUMENTARY REMEMBERING ADELE, AND WILL EXECUTE ASSOCIATED EDUCATIONAL IMPACT CAMPAIGNS. THESE FILMS WILL BE SHOWN IN COMMUNITY SETTINGS ACROSS THE COUNTRY TO INCREASE AWARENESS OF, AND PARTICIPATION IN, ALZHEIMER'S CLINICAL RESEARCH. WE HAVE EXPANDED OUR WRITTEN AND MULTIMEDIA CONTENT OF KEY RESEARCH FINDINGS, PROMOTING AND SHARING THIS INFORMATION THROUGH OUR WEBSITE AND SOCIAL MEDIA PLATFORMS, INCLUDING VIDEO AND YOUTUBE. BRIGHTFOCUS INFOGRAPHICS VISUALLY COMMUNICATE INFORMATION ON ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND WE PROVIDE ACCESSIBLE CONTENT TRANSCRIPTS AND RESOURCES. IN THE SPRING OF 2020, WE LAUNCHED A FULL SECTION OF OUR WEBSITE DEDICATED TO SHARING EXCLUSIVE CONTENT ON COVID-19 FOR FAMILIES IMPACTED BY DISEASES OF MIND AND SIGHT. MORE SPECIFICALLY, EACH OF BRIGHTFOCUS' THREE PROGRAM AREAS MAILS AWARENESS-RAISING MATERIALS TO HUNDREDS OF THOUSANDS OF NATIONAL HOUSEHOLDS, WITH MESSAGES FOCUSING ON: - RISK FACTORS AND SYMPTOM RECOGNITION THROUGH PUBLIC AWARENESS AND STEPS THE PUBLIC SHOULD TAKE THAT MAY HELP REDUCE THEIR RISK. - LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE. - RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS THE DISEASE. BRIGHTFOCUS REGULARLY INTERACTS WITH ADVOCACY ORGANIZATIONS, GOVERNMENTS AT ALL LEVELS, AND MEMBERS OF THE MEDIA, TO CALL GREATER ATTENTION TO DISEASES OF MIND AND SIGHT AND SHARE THE LATEST RESEARCH AND BEST PRACTICES WITH PUBLIC FIGURES AND KEY STAKEHOLDERS. THROUGH OUR OWN OUTREACH EFFORTS, AS WELL AS VIA ACTIVE ROLES IN ADVOCACY COALITIONS, WE HELP ADVANCE THE CAUSE OF PIONEERING SCIENCE AND BETTER POSITION BRIGHTFOCUS AS A RESOURCE FOR THOSE STRUGGLING WITH AND SEARCHING FOR CURES FOR THESE TERRIBLE DISEASES. BRIGHTFOCUS IS THE PRESENTING SPONSOR OF THE HELEN KELLER PRIZE FOR VISION RESEARCH, ONE OF THE MOST PRESTIGIOUS RECOGNITIONS IN THE FIELD. SELECTED BY A PANEL OF THE WORLD'S FOREMOST VISION SCIENTISTS, EACH YEAR'S LAUREATE IS HONORED FOR A GROUNDBREAKING CONTRIBUTION OR DISCOVERY TO SAVE SIGHT. BRIGHTFOCUS BEGAN ITS SPONSORSHIP IN 2015 TO CALL GREATER ATTENTION TO VISION RESEARCH ACROSS THE PRIVATE AND PUBLIC SECTORS. BRIGHTFOCUS WAS HONORED IN 2023 FOR ITS CONTRIBUTIONS TO ADVANCING GLOBAL VISION RESEARCH BY THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY (ARVO) FOUNDATION.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	ALZHEIMER'S DISEASE RESEARCH (ADR) - ALZHEIMER'S DISEASE IS THE ONLY CAUSE OF DEATH AMONG THE TOP 10 IN AMERICA WITHOUT A WAY TO PREVENT, CURE, OR EVEN SLOW ITS PROGRESSION. IT IS AN IRREVERSIBLE DEGENERATION OF THE BRAIN THAT CAUSES DISRUPTIONS IN MEMORY, COGNITION, PERSONALITY, AND OTHER FUNCTIONS AND INEVITABLY LEADS TO DEATH. AN ESTIMATED 55 MILLION PEOPLE WORLDWIDE HAVE ALZHEIMER'S DISEASE OR OTHER DEMENTIAS, WITH WOMEN AND OTHER MINORITY GROUPS MOST AT-RISK. BRIGHTFOCUS' ALZHEIMER'S DISEASE RESEARCH (ADR) PROGRAM FUNDS RESEARCH FOCUSED ON UNDERSTANDING THE CAUSES OF ALZHEIMER'S DISEASE, ITS EARLY DETECTION, AND TREATMENTS TO HELP SLOW OR STOP ITS PROGRESSION, AND ULTIMATELY TO PREVENT THE DISEASE ALTOGETHER. ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE. SINCE ITS INCEPTION, BRIGHTFOCUS HAS CONTRIBUTED MORE THAN $175 MILLION TO THE CONQUERING OF ALZHEIMER'S DISEASE. DURING THE FISCAL YEAR THAT ENDED MARCH 31, 2023, ADR AWARDED $6,394,521 IN PEER-REVIEWED GRANT AWARDS TO 26 NEW RESEARCH PROJECTS AND 8 OTHER AWARDS TO MAKE A TOTAL OF 34 GRANTS AT $7,755,537 TOTAL IN FUNDING. NOTABLE PROJECTS INCLUDE: HYPERTENSION AND LIFESTYLE EFFECTS ON RISK OF ALZHEIMER'S (INCLUDING LIPIDS); DRUG DISCOVERY AND BIOMARKERS; THE ROLE OF INFLAMMATION, MICROGLIA, AND VASCULAR HEALTH IN DISEASE RISK; LOOKING AT THE MITOCHONDRIA AND CELL ENERGY DEFICIENCIES; THE ROLE OF SLEEP DISTURBANCES CAUSING AN INCREASED RISK OF COGNITIVE ISSUES; DIFFERENCES IN GENETICS AND DISEASE RISK FOR UNDERREPRESENTED POPULATIONS; AND BETTER USE OF MODERN TECHNOLOGIES, INCLUDING BIG DATA/AI AND SYSTEMS GENETICS ANALYSIS FOR INCREASED AND DECREASED RISKS. ADDITIONAL INFORMATION ABOUT SPECIFIC PROJECTS IS INCLUDED IN SCHEDULES F & I. BRIGHTFOCUS IS HONORED TO HAVE SUPPORTED THE EARLY RESEARCH OF TWO NOBEL PRIZE WINNERS, DR. STANLEY PRUSINER AND DR. PAUL GREENGARD, WHOSE WORK HAS BEEN INSTRUMENTAL TO OUR CURRENT UNDERSTANDING OF ALZHEIMER'S DISEASE. BRIGHTFOCUS CONTINUES ITS PARTNERSHIP WITH THE ACADEMIC JOURNAL "MOLECULAR NEURODEGENERATION," THE OFFICIAL JOURNAL OF BRIGHTFOCUS FOUNDATION AND THE NUMBER ONE OPEN-ACCESS JOURNAL IN NEUROSCIENCE. THE JOURNAL PUBLISHES TECHNICAL PAPERS RELATED TO NEURODEGENERATION IN THE THREE DISEASE AREAS. TO ACCELERATE SCIENTIFIC PROGRESS, IT IS AN "OPEN ACCESS" JOURNAL, AND ALL CONTENT IS AVAILABLE FREE OF CHARGE. THIS OPEN ACCESS ENSURES MAXIMUM REACH OF JOURNAL CONTENT TO SCIENTISTS AND HEALTH CARE PROVIDERS WORLDWIDE. IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, ADR PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.
FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:	MACULAR DEGENERATION RESEARCH (MDR) - AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF VISION LOSS IN THE UNITED STATES. IT DESTROYS THE MACULA, THE PART OF THE EYE THAT PROVIDES SHARP, CENTRAL VISION NEEDED FOR SEEING OBJECTS CLEARLY. THE MOST COMMON EYE CONDITION IN PEOPLE AGE 60 AND OLDER, IT CAN LEAD TO VISION LOSS IN ONE OR BOTH EYES, MAKING IT DIFFICULT TO RECOGNIZE FACES, DRIVE A CAR, OR READ. AT LEAST 20 MILLION AMERICANS HAVE SOME TYPE OF MACULAR DEGENERATION, INCLUDING BOTH THE EARLY AND LATER STAGES OF THE WET AND DRY TYPES. MACULAR DEGENERATION RESEARCH (MDR ), A PROGRAM OF BRIGHTFOCUS, HAS AWARDED NEARLY $50 MILLION TO SCIENTISTS STUDYING THE DISEASE. THE LATEST RESEARCH IS FOCUSED ON NOVEL TREATMENTS FOR THE DISEASE, UNDERSTANDING ITS CAUSES AND PROGRESSION, PREDICTION METHODS AND DISEASE MODELING, DRUG THERAPIES, THE ROLE OF THE METABOLISM IN DISEASE RISK, GENES, THE ROLE OF THE IMMUNE RESPONSE IN DISEASE RISK, AND NEW IMAGING, MACHINE LEARNING AND SCREENING TECHNIQUES. MDR GRANTS ARE AVAILABLE TO MACULAR DEGENERATION RESEARCHERS WORLDWIDE. MDR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT. DURING THE FISCAL YEAR ENDING MARCH 31, 2023, MDR AWARDED $3,839,035 IN PEER-REVIEWED GRANT AWARDS TO 13 NEW RESEARCH PROJECTS, WITH 5 ADDITIONAL PROJECTS THAT TAKE THE TOTAL FUNDING TO 18 GRANTS AT $4,039,275. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I. IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, MDR PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THIS DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	NATIONAL GLAUCOMA RESEARCH (NGR) - GLAUCOMA IS THE SECOND LEADING CAUSE OF BLINDNESS WORLDWIDE. ACCORDING TO A RECENT REPORT FROM THE WORLD HEALTH ORGANIZATION, APPROXIMATELY 80 MILLION PEOPLE AROUND THE WORLD HAVE GLAUCOMA. MORE THAN THREE MILLION AMERICANS OVER THE AGE OF 40 ARE LIVING WITH GLAUCOMA, WITH AN ESTIMATED 2.7 MILLION HAVE OPEN-ANGLE GLAUCOMA, THE MOST COMMON TYPE. IN THE UNITED STATES, GLAUCOMA IS A LEADING CAUSE OF BLINDNESS AMONG BLACK AND HISPANIC AMERICANS. WITH EARLY DETECTION AND TREATMENT, GLAUCOMA OFTEN CAN BE MANAGED TO PROTECT EYES FROM MORE SERIOUS VISION LOSS. IT IS ESTIMATED THAT ONLY HALF OF THE PEOPLE LIVING WITH GLAUCOMA ARE AWARE THAT THEY HAVE THE DISEASE. BRIGHTFOCUS' NGR PROGRAM HAS AWARDED MORE THAN $49 MILLION WORLDWIDE FOR THE STUDY OF GLAUCOMA. NGR-SUPPORTED RESEARCH HAS BEEN FOCUSED ON THE EYE-BRAIN CONNECTION, HOW PRESSURE BUILDUP IN THE EYE CAN AFFECT SYNAPTIC NERVE COMMUNICATIONS, NEUROPROTECTION, AND OPTIC NERVE REGENERATION, DISCOVERING GLAUCOMA RISK GENES, AI/DEEP LEARNING AND ADAPTIVE OPTICS, SLEEP DISTURBANCE AND RISK OF DEVELOPING GLAUCOMA, DEVELOPING EARLY GLAUCOMA SCREENING, AND PURSUING NOVEL GENETIC COUNSELING AND COMMUNICATION STRATEGIES, AMONGST OTHER INNOVATIVE PURSUITS. BRIGHTFOCUS' NATIONAL GLAUCOMA RESEARCH (NGR) GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT. DURING THE FISCAL YEAR ENDING MARCH 31, 2023, NGR AWARDED $2,034,241 IN PEER-REVIEWED GRANT AWARDS FOR 11 NEW PROJECTS AND 2 OTHER AWARDS TO MAKE A TOTAL OF 13 GRANTS AT $2,526,791 IN FUNDING. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I. IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, BRIGHTFOCUS' NGR PROGRAM PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.
FORM 990, PART VI, SECTION B, LINE 11B	A DRAFT OF THE FEDERAL FORM 990 IS DISTRIBUTED TO THE AUDIT COMMITTEE FOR REVIEW PRIOR TO BEING SUBMITTED TO THE INTERNAL REVENUE SERVICE. THE DRAFT FEDERAL FORM 990 IS DISTRIBUTED EARLY ENOUGH TO PROVIDE EACH COMMITTEE MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUBMISSION OF QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FINAL FEDERAL FORM 990 IS DISTRIBUTED TO EACH MEMBER OF THE FULL BOARD OF DIRECTORS PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE. THE DRAFT OR FINAL FEDERAL FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-MAIL, OR FAX.
FORM 990, PART VI, SECTION B, LINE 12C	BRIGHTFOCUS HAS ALL EMPLOYEES, OFFICERS, AND DIRECTORS AGREE TO THE CODE OF CONDUCT THAT INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST AND IMPLEMENTATION POLICY. EACH BOARD DIRECTOR, OFFICER, AND EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNUALLY. EMPLOYEES MEET ANNUALLY WITH THE BRIGHTFOCUS' CHIEF COMPLIANCE OFFICER TO REVIEW THEIR CONFLICT OF INTEREST STATEMENTS, AND GIVE AN ANNUAL CONFLICT OF INTEREST COMPLIANCE REPORT TO THE BOARD CHAIR AND VICE CHAIR. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE PRESIDENT/CEO AND/OR BRIGHTFOCUS' LEGAL COUNSEL AND, IF APPROPRIATE AND NECESSARY, THEN TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION. THE DIRECTOR'S AND OFFICER'S STATEMENTS ARE REVIEWED BY THE BRIGHTFOCUS LEGAL COUNSEL. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION. AT THE TIME OF THE BRIGHTFOCUS DISCUSSION AND DECISION CONCERNING A CONFLICT OF INTEREST, THE CONFLICTED PARTY IS NOT PRESENT IN THE MEETING.
FORM 990, PART VI, SECTION B, LINE 15	BRIGHTFOCUS' BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES SALARY AND BENEFITS FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS AND KEY EMPLOYEES. ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE BRIGHTFOCUS FISCAL YEAR. BEFORE APPROVING THE COMPENSATION OF THE PRESIDENT/CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY BRIGHTFOCUS TO THE PRESIDENT/CEO IS REASONABLE IN LIGHT OF THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR BRIGHTFOCUS, IF APPLICABLE. THE PRESIDENT/CEO IS EVALUATED ANNUALLY BY THE BOARD OF DIRECTORS THROUGH THE USE OF AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, (DEVELOPED WITH ADVICE FROM BOARD SOURCE) THAT INCLUDES A SELF ASSESSMENT AND A BOARD OF DIRECTORS ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES AND DELIVERABLES. IN ADDITION, THE BOARD OF DIRECTORS PERIODICALLY ENGAGES AN OUTSIDE CONSULTANT TO OBTAIN AND CONSIDER APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN LIKE CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD OF DIRECTORS SHALL CONSIDER TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY BRIGHTFOCUS TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE BRIGHTFOCUS BOARD DISCUSSION AND DECISION CONCERNING THE PRESIDENT/CEO'S COMPENSATION, THE PRESIDENT/CEO IS NOT PRESENT IN THE MEETING. THE BOARD SHALL SET FORTH THE BASIS FOR ITS DECISIONS WITH RESPECT TO COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DECISIONS ARE MADE, INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS FOR DETERMINING THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE IN LIGHT OF THE EVALUATION AND COMPARABILITY DATA. THE PRESIDENT/CEO IS CHARGED WITH THE SETTING OF SALARIES OF ALL OTHER EMPLOYEES IN ACCORDANCE WITH A COMPENSATION STRUCTURE AND BUDGET APPROVED BY THE BOARD OF DIRECTORS. THE PRESIDENT/CEO AND HUMAN RESOURCES REVIEW EMPLOYEE COMPENSATION AND BENEFITS THAT INCLUDE KEY EMPLOYEES, BY PERIODICALLY ENGAGING AN OUTSIDE CONSULTANT TO CONDUCT COMPENSATION AND BENEFIT BENCHMARKING STUDIES THAT INCLUDE VARIOUS REGIONAL AND NATIONAL NON-PROFIT COMPENSATION REPORTS AND SURVEYS. COMPENSATION DELIBERATIONS AND DECISIONS INCLUDE THE REVIEW OF SELF AND SUPERVISORY EVALUATIONS OF EMPLOYEE PERFORMANCE COMPARED TO SET INDIVIDUAL AND ORGANIZATIONAL GOALS.
FORM 990, PART VI, SECTION C, LINE 19	BRIGHTFOCUS MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF INCORPORATION AND BYLAWS, THE FEDERAL FORM 1023, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, CONFLICT OF INTEREST POLICY, AUDITED FINANCIAL STATEMENTS AND FEDERAL FORM 990 AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, AND FEDERAL FORM 990 ON OUR WEBSITE.
FORM 990, PART XI, LINE 9:	RECOVERIES OF PRIOR YEAR GRANTS 1,028,552. CHANGE IN PRESENT VALUE OF GRANTS 267,164.
SCHEDULE F, PART II, LINE 1, COLUMN D:	REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LUCIA CHAVEZ-GUTIERREZ, PHD, ENTITLED: (A2023005S) ELUCIDATING THE MECHANISMS OF ACTION OF GAMMA-SECRETASE MODULATORS (GSMS) TO FACILITATE STRUCTURE-BASED DESIGN OF NEXT-GENERATION THERAPEUTICS. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS LINKED TO THE BUILD-UP OF LONGER, AGGREGATION-PRONE AMYLOID-BETA (A-BETA) PEPTIDES IN THE BRAIN. GAMMA-SECRETASE DYSREGULATION LEADING TO ENHANCED PRODUCTION OF LONGER A-BETAS CAUSES AD. GAMMA-SECRETASE MODULATORS PROMOTE THE PRODUCTION OF SHORTER A-BETAS, WHILE SPARING CRITICAL (GAMMA-SECRETASE) BIOLOGICAL ROLES. THESE MOLECULES ARE PROMISING AGENTS IN THE FIGHT AGAINST AD; HOWEVER, A LACK OF UNDERSTANDING OF THEIR MODES OF ACTION HAVE LIMITED THEIR DEVELOPMENT. HERE, WE WILL DEFINE THE MODE(S) OF ACTION OF GAMMA-SECRETASE MODULATORS AND FOSTER THERAPEUTIC DEVELOPMENT. GRANT AWARDED: $300,000, FLANDERS INSTITUTE FOR BIOTECHNOLOGY, (VIB), GENT, BELGIUM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023005S REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARTA CASQUERO-VEIGA, PHD, ENTITLED: (A2023012F) DEVELOPMENT OF MULTIMODAL NEUROIMAGING BIOMARKERS OF THE PRO-COAGULANT STATE IN ALZHEIMER'S DISEASE (NIPAD). INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) PATHOPHYSIOLOGY INCLUDES AN EARLY HEMOSTATIC DYSREGULATION, INDUCING A PRO-THROMBOTIC MILIEU. CONSEQUENTLY, AD-PATIENTS' BRAINS SHOW INCREASED FIBRIN LEVELS AND DEGRADATION-RESISTANT CLOTS, WHICH CONTRIBUTES TO NEURONAL DEATH. THESE PROCESSES APPEAR EARLY IN AD'S COURSE, BUT NOT IN ALL PATIENTS. THIS STUDY AIMS TO DEVELOP NEW GENERATION PROBES TO VISUALIZE THE PRO-COAGULANT COMPONENTS ACCUMULATED IN THE AD BRAIN, BY IN VIVO NON-INVASIVE MULTIMODAL IMAGING. ULTIMATELY, OUTCOMES WILL ENABLE CLINICIANS TO PRESCRIBE A SUITABLE TREATMENT TO AMELIORATE AD'S PROGRESSION. GRANT AWARDED: $200,000, INSTITUTO DE INVESTIGACION SANITARIA - FUNDACION JIMENEZ DIAZ, MADRID, SPAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023012F REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY QI WANG, PHD, ENTITLED: (A2023018F) RESTORING MITOCHONDRIAL HOMEOSTASIS AS A THERAPY OF ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: DEFECTS IN MITOCHONDRIA PRECEDE THE ONSET OF DEMENTIA BY DECADES AND ARE INVOLVED IN MULTIPLE ASPECTS OF ALZHEIMER'S DISEASE (AD) PATHOGENESIS. I AIM TO TEST WHETHER ACTIVATING THE BENEFICIAL MITOCHONDRIAL STRESS RESPONSES WITH A COMPOUND NAMED 9-TB COULD IMPROVE AD PATHOLOGIES. I WILL INVESTIGATE 9-TB'S EFFECTS ON MITOCHONDRIAL FUNCTION, MAIN COGNITIVE AND BIOMEDICAL MANIFESTATIONS OF AD IN A MOUSE MODEL. I WILL USE ADVANCED MULTI-OMICS APPROACH TO FULLY REVEAL 9-TB'S MECHANISMS OF ACTION AND VALIDATE ITS MECHANISM USING IN VITRO, EX VIVO AND IN SILICO SYSTEMS, FULFILLING THE REQUIREMENTS FOR CLINICAL TRIALS. GRANT AWARDED: $200,000, SWISS FEDERAL INSTITUTE OF TECHNOLOGY LAUSANNE, SWITZERLAND. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023018F REGION: MIDDLE EAST (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ARIEL GILAD, PHD, ENTITLED: (A2023024S) BRAIN-WIDE NETWORK DYSFUNCTIONS IN ALZHEIMER'S DISEASE OF INDIVIDUAL MICE. INVESTIGATOR'S SUMMARY: A HALLMARK OF ALZHEIMER'S DISEASE (AD) IS ABNORMAL BRAIN-WIDE NETWORKS THAT DIFFER ACROSS AND WITHIN PATIENTS. HERE, WE AIM TO USE AN AD MOUSE MODEL TO RECORD BRAIN-WIDE NETWORKS IN MICE DURING AD-RELATED COGNITIVE TASKS. BY USING AN INDIVIDUAL APPROACH AND TRACK EACH MOUSE THROUGHOUT ITS LIFESPAN, WE BELIEVE THAT EACH MOUSE WILL DISPLAY BRAIN-WIDE DYSFUNCTION THAT IS MODULATED BASED ON AD PROGRESSION AND INDIVIDUAL TRAITS. WE AIM TO OUTLINE KEY BRAIN AREAS THAT MAY BE TARGETED IN INDIVIDUAL HUMAN PATIENTS USING DEEP-BRAIN STIMULATION, THUS INCREASING THE QUALITY OF LIFE FOR MILLIONS OF PEOPLE GRANT AWARDED: $300,000, HEBREW UNIVERSITY OF JERUSALEM, ISRAEL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023024S REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LOUISE VAN DER WEERD, PHD, ENTITLED: (A2023026S) IRON SPREADING PATTERNS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: WE KNOW THAT IRON ACCUMULATES IN THE BRAINS OF PATIENTS WITH ALZHEIMER'S DISEASE (AD). THIS PROCESS STRONGLY PREDICTS HOW FAST A PATIENT'S COGNITIVE FUNCTION WILL DECLINE. HOWEVER, WE DO NOT YET KNOW WHERE IN THE BRAIN THE ACCUMULATION STARTS, AND HOW THE ACCUMULATION SPREADS. THAT MAKES IT DIFFICULT TO DEVELOP MEASUREMENTS THAT CAN HELP TO PREDICT THE DISEASE COURSE FOR INDIVIDUAL PATIENTS. IN THIS PROJECT WE WILL DEVELOP AN ATLAS OF THE BRAIN THAT SHOWS HOW IRON ACCUMULATES AS AD PROGRESSES OVER TIME. WE DO THAT BY STUDYING HUNDREDS OF BRAIN DONORS WITH VARYING DEGREES OF AD. GRANT AWARDED: $299,354, LEIDEN UNIVERSITY MEDICAL CENTER, LEIDEN, NETHERLANDS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023024S REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH CONFERENCE SUPPORT. GRANT AWARDED: $99,353, THE 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S & PARKINSON'S DISEASES, GOTHENBURG, SWEDEN. REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE. GRANT AWARDED: $10,000, FINGERS BRAIN HEALTH INSTITUTE, STOCKHOLM, SWEDEN. REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DR. GAELLE CHETELAT ENTITLED: (CA2021013) SEX DIFFERENCES IN RISK PROFILES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM. INVESTIGATOR'S SUMMARY: THIS PROJECT WILL AIM TO MODEL COGNITIVE RESILIENCE IN RODENTS BY COMBINING A RAT MODEL OF SUCCESSFUL AGING WITH A MODEL OF EARLY ALZHEIMER'S DISEASE (AD). THE HYPOTHESIS TESTS WHETHER THESE RATS ARE RESILIENT TO AD PATHOLOGY, RESULTING IN INTACT COGNITION COMPARED TO AD RATS. THE INVOLVEMENT OF THE SEROTONERGIC SYSTEM WILL BE EVALUATED TO DETERMINE POTENTIAL THERAPEUTIC TARGETS THAT MAY PROMOTE RESILIENCE TO AD. GRANT AWARDED: $25,000, FONDATION VAINCRE ALZHEIMER, PARIS, FRANCE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2021013
SCHEDULE F, PART II, LINE 1, COLUMN D, CONTINUED:	REGION: EUROPE (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KAREN PEYNSHAERT, PHD, ENTITLED: (G2023002F) EXPLORING ICG-MEDIATED ILM PHOTODISRUPTION AS A TOOL TO BOOST RETINAL GANGLION CELL ENGRAFTMENT. INVESTIGATOR'S SUMMARY: THIS PROJECT EXPLORES AN INNOVATIVE BIOPHOTONIC APPROACH TO MANIPULATE THE INNER LIMITING MEMBRANE (ILM), A BARRIER WHICH GREATLY HINDERS THE RETINAL ENTRY OF DONOR RGCS FOLLOWING INTRAVITREAL INJECTION. BY CONTROLLED PERFORATION OF THE ILM, WE AIM TO ENHANCE THE MIGRATION OF RGCS INTO THE RETINA WHILE MAINTAINING ILM'S CUES NECESSARY FOR THEIR SUBSEQUENT DEVELOPMENT. GRANT AWARDED: $150,000, GHENT UNIVERSITY, GENT, BELGIUM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023002F REGION: NORTH AMERICA (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ADRIANA DI POLO, PHD, ENTITLED: (G2023005S) DISEASE-MODIFYING MITOCHONDRIAL UNCOUPLERS: A NEW THERAPEUTIC STRATEGY FOR GLAUCOMA. INVESTIGATOR'S SUMMARY: MITOCHONDRIAL DYSFUNCTION IS A KEY FEATURE OF NEURONAL DAMAGE IN GLAUCOMA. THIS PROPOSAL WILL TEST THE POTENTIAL OF MILD MITOCHONDRIA UNCOUPLERS AS DISEASE-MODIFYING AGENTS TO REDUCE OXIDATIVE STRESS, IMPROVE CALCIUM HOMEOSTASIS, AND PROMOTE REPAIR PATHWAYS. THE OUTCOME OF THIS STUDY WILL PROVIDE ROBUST PROOF-OF-PRINCIPLE DATA AND OPEN NEW OPPORTUNITIES FOR CLINICAL TESTING IN GLAUCOMA PATIENTS. GRANT AWARDED: $200,000, UNIVERSITY OF MONTREAL, CANADA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023005S REGION: EUROPE (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SILVIA MARINELLI, PHD, ENTITLED: (G2023006S) A NEW OPTIMIZED FORM OF NERVE GROWTH FACTOR: AN ANTI-INFLAMMATORY AND NEUROPROTECTIVE DRUG CANDIDATE FOR GLAUCOMA. INVESTIGATOR'S SUMMARY: WE DEVELOPED AN OPTIMIZED NERVE GROWTH FACTOR, PAINLESS NGF (NGFP), THAT HAS THE SAME NEUROPROTECTIVE PROPERTIES AS NATURAL NGF BUT LACKS ADVERSE EFFECTS, SUCH AS PAIN AND CELL DEATH SIGNALLING. NGFP, WITHOUT THE PITFALLS OF NATURAL NGF, IS A PROMISING THERAPEUTIC CANDIDATE FOR GLAUCOMA, ABLE TO RESCUE RGC DEGENERATION THROUGH A SYNERGISTIC ACTION OF NEUROPROTECTION AND INFLAMMATORY MODULATION GRANT AWARDED: $200,000, FONDAZIONE EBRI "RITA LEVI-MONTALCINI", ROME, ITALY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023006S REGION: EUROPE (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DARRYL OVERBY, PHD, ENTITLED: (G2023011S) MICROENVIRONMENTAL REGULATION OF BARRIER FUNCTION IN SCHLEMM'S CANAL ENDOTHELIAL CELLS. INVESTIGATOR'S SUMMARY: THE ONLY WAY TO TREAT GLAUCOMA IS TO REDUCE EYE PRESSURE, BUT THE FACTORS CONTROLLING EYE PRESSURE ARE NOT UNDERSTOOD. OUR LAB HAS SHOWN THAT EYE PRESSURE IS PARTLY REGULATED BY A LAYER OF SPECIALISED CELLS THAT CREATE A BARRIER AGAINST FLUID DRAINAGE FROM THE EYE. WE AIM TO RECREATE THIS CELLULAR BARRIER IN THE LAB, WHICH WILL OPEN NEW AVENUES FOR RESEARCH AND DEVELOPMENT TARGETING THIS BARRIER. GRANT AWARDED: $184,242, IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE, LONDON, UNITED KINGDOM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023011S REGION: EUROPE (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DARRYL OVERBY, PHD, ENTITLED: (CG2020003) DEVELOPING NEW DRUGS TO LOWER EYE PRESSURE IN GLAUCOMA. INVESTIGATOR'S SUMMARY: OUR RESEARCH HAS IDENTIFIED A PARTICULAR CELL TYPE (SCHLEMM'S CANAL CELLS) THAT REGULATE EYE PRESSURE BY CONTROLLING THE DRAINAGE OF AQUEOUS HUMOR FROM THE EYE. IN THIS PROJECT, WE WILL DEVELOP AND APPLY NOVEL SCREENING TECHNOLOGIES TO IDENTIFY NEW DRUGS TO LOWER EYE PRESSURE BY IMPROVING AQUEOUS HUMOR DRAINAGE ACROSS SCHLEMM'S CANAL CELLS. GRANT AWARDED: $97,975, IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE, LONDON, UNITED KINGDOM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CG2020003 REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MATTHEW RUTAR, PHD, ENTITLED: (M2023009N) INVESTIGATING THE ROLE OF NEUTROPHIL EXTRACELLULAR TRAPS IN NEOVASCULAR AMD. INVESTIGATOR'S SUMMARY: NEOVASCULAR AMD (NAMD) IS A MAJOR CAUSE OF BLINDNESS WITH FEW AVAILABLE TREATMENTS. OUR CENTRAL HYPOTHESIS IS THAT DYSREGULATION OF NEUTROPHIL EXTRACELLULAR TRAPS (NETS) PROMOTES INFLAMMATION AND DEGENERATION IN NAMD, THUS REPRESENTING A NOVEL TARGET FOR DIAGNOSTIC BIOMARKERS AND THERAPEUTIC INTERVENTIONS. WE DETERMINE A ROLE FOR NETS USING EXPERIMENTAL MODELS AND AMD DONOR TISSUE, AND EVALUATE THE POTENTIAL OF FIRST-GENERATION INHIBITORS OF NET ACTIVITY IN CURTAILING INFLAMMATION AND PATHOLOGY IN CNV. GRANT AWARDED: $334,938, UNIVERSITY OF CANBERRA, BRUCE, AUSTRALIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023009N
SCHEDULE I, PART II, LINE 1, COLUMN (H):	NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ZAHRA SHIRZADI, PHD, ENTITLED: (A2023001F) NOVEL TOOLS TO DISSECT THE MULTI-FACTORIAL ETIOLOGIES OF WHITE MATTER INJURY IN AGING AND ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE BRAIN'S WHITE MATTER IS COMPOSED OF MILLIONS OF BUNDLES OF NERVE FIBERS THAT CONNECT NEURONS IN DIFFERENT BRAIN REGIONS INTO FUNCTIONAL CIRCUITS. THEREFORE, ANY DAMAGE TO THESE FIBERS CAN AFFECT NORMAL BRAIN FUNCTION. IT IS VERY COMMON TO OBSERVE SIGNS OF WHITE MATTER INJURY IN BRAIN IMAGES OF PRECLINICAL AND SYMPTOMATIC ALZHEIMER'S DISEASE (AD) PATIENTS, YET IT IS UNCLEAR WHY THIS INJURY OCCURS. FOLLOWING UP ON OUR RECENT STUDIES IN FAMILIAL AD, WE WILL INVESTIGATE WHETHER AD MARKERS INCLUDING AMYLOID ACCUMULATION AND BRAIN TISSUE LOSS CAN DESCRIBE WHITE MATTER INJURY IN AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023001F NAME OF ORGANIZATION OR GOVERNMENT: BAYLOR COLLEGE OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAHEUN CHUNG, PHD, ENTITLED: (A2023002F) EXPLORING THE PROTECTIVE ROLE OF THE BIG TAU ISOFORM IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: AS COGNITIVE DECLINE IS HIGHLY CORRELATED WITH THE SEVERITY OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE, PROTECTING TAU FROM ABNORMAL CHANGES MAY BRING THERAPEUTIC BENEFITS. WHILE THERE IS NO EFFECTIVE TAU-TARGETING TREATMENT, I RECENTLY DISCOVERED THAT AN UNDERSTUDIED TAU ISOFORM, ABUNDANT IN THE BRAIN REGION SPARED FROM TAU PATHOLOGY, IS LESS LIKELY TO BECOME PATHOLOGICALLY ALTERED. AS SUCH, I PROPOSE TO EXAMINE IF THIS TAU ISOFORM IS CRUCIAL IN PREVENTING THE DEVELOPMENT OF TAU PATHOLOGY IN THE BRAIN, AND IF IT HAS ANY UNIQUE INTERACTING PROTEIN PARTNERS THAT FACILITATE SUCH A PHENOMENON. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023002F NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAVID GATE, PHD, ENTITLED: (A2023003S) PROTEOGENOMICS TO STUDY ADAPTIVE IMMUNITY IN NEURODEGENERATIVE DISEASE. INVESTIGATOR'S SUMMARY: THIS PROPOSAL WILL UTILIZE A NOVEL PROTEOGENOMICS APPROACH TO EXPLORE THE ROLE OF ADAPTIVE IMMUNE T CELLS IN THE PATHOPHYSIOLOGY OF AGE-RELATED NEURODEGENERATION. THIS APPROACH AIMS TO IDENTIFY NEUROIMMUNOLOGIC DISEASE MECHANISMS AND THERAPEUTIC TARGETS FOR THESE DEVASTATING DISEASES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023003S NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MEAGHAN MORRIS, MD, PHD, ENTITLED: (A2023004S) EXPLORING THE ORIGINS OF TAU PATHOLOGY IN HUMAN BRAIN: MOLECULAR SIGNATURES OF AGING AND NEURODEGENERATION IN THE LOCUS CERULEUS. INVESTIGATOR'S SUMMARY: THE SPREAD OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE IS ASSOCIATED WITH PROGRESSIVE COGNITIVE DECLINE. HOWEVER, THE MOLECULAR EVENTS SURROUNDING THE EARLIEST FORMATION AND SPREAD OF TAU PATHOLOGY IN THE HUMAN BRAIN ARE LARGELY UNEXPLORED. THIS STUDY WILL EXAMINE THE MOLECULAR ENVIRONMENT ASSOCIATED WITH AGING AND EARLY ACCUMULATION OF TAU PATHOLOGY IN HUMAN BRAIN, AS WELL AS THE EARLIEST SPREAD OF TAU PATHOLOGY IN AGING AND ALZHEIMER'S DISEASE. INSIGHT INTO THIS EARLY TAU FORMATION COULD PROVIDE TARGETABLE PATHWAYS TO PREVENT THE FORMATION OR SPREAD OF TAU PATHOLOGY IN THE BRAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023004S NAME OF ORGANIZATION OR GOVERNMENT: CORNELL UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MATTHEW ISAACSON, PHD, ENTITLED: (A2023006F) IMAGING NEURAL ACTIVITY CHANGES UNDERLYING THE ACUTE RESCUE OF MEMORY FUNCTION AFTER IMPROVING CEREBRAL BLOOD FLOW IN ALZHEIMER'S DISEASE MOUSE MODELS. INVESTIGATOR'S SUMMARY: USING VISUAL AND SPATIAL BEHAVIORAL TASKS DURING FUNCTIONAL BRAIN IMAGING, WE WILL CHARACTERIZE LEARNING AND MEMORY DEFICITS AND THEIR NEURAL CORRELATES IN AN ALZHEIMER'S DISEASE MOUSE MODEL. WITH A PREVIOUSLY ESTABLISHED ACUTE TREATMENT TO IMPROVE BLOOD FLOW IN THE BRAIN THAT IMPROVES MEMORY, WE WILL GAIN NEW INSIGHT INTO HOW IMPROVED COGNITIVE ABILITY MANIFESTS IN NEURAL ACTIVITY CHANGES AND UNCOVER DISEASE-RELEVANT FAILURE MODES OF NEURAL CIRCUITRY THAT WILL INFORM HOW THESE CIRCUITS COULD BE THERAPEUTICALLY MANIPULATED TO RESTORE COGNITIVE ABILITY IN NEURODEGENERATIVE DISORDERS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023006F NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JOOST RIPHAGEN, MD, PHD, ENTITLED: (A2023007F) MEYNERT TO MAYHEM? THE TEMPORAL-SPATIAL EVOLUTION OF EARLY TAU PATHOLOGY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: FOR OPTIMAL TREATMENT OF ALZHEIMER'S DISEASE (AD) IT IS CRUCIAL TO IDENTIFY PEOPLE AT RISK OF AD EARLY, BEFORE IRREVERSIBLE BRAIN DAMAGE OCCURS. A SMALL REGION AT THE BOTTOM OF THE BRAIN (BASAL FOREBRAIN) IS ONE OF THE FIRST REGIONS TO ACCUMULATE MISFOLDED AD TAU PROTEINS AND IS CRITICAL FOR MEMORY FUNCTION. WE WILL USE ADVANCED BRAIN IMAGING METHODS (MRI AND PET) TO DETECT SUBTLE CHANGES IN THIS REGION AND PREDICT DISEASE PROGRESSION. FINDINGS FROM THIS STUDY HAVE THE POTENTIAL TO UNDERSTAND MECHANISMS OF DISEASE PROGRESSION AND MOVE DETECTION AND TREATMENT TO EARLIER STAGES OF THE DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023007F NAME OF ORGANIZATION OR GOVERNMENT: WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY TILL ZIMMER, PHD, ENTITLED: (A2023008F) MOLECULAR MECHANISMS AND EFFECTS OF ALZHEIMER'S-RELATED LIPID DYSREGULATION IN ASTROCYTES. INVESTIGATOR'S SUMMARY: THE BRAIN IS FULL OF FATS, ALSO CALLED LIPIDS, WHICH ARE DYSREGULATED IN ALZHEIMER'S DISEASE (AD). LIPID SUPPLY BY ASTROCYTES IS VITAL TO THE FUNCTION AND SURVIVAL OF NEURONS AND NEURONAL DEGENERATION IS THOUGHT TO CAUSE AD-RELATED SYMPTOMS. IMPROPER LIPID SUPPORT BY ASTROCYTES IN AD COULD CAUSE NEURONS TO BE DYSFUNCTIONAL OR DEGENERATE. TO BETTER UNDERSTAND THESE MECHANISMS, WE WILL STUDY HOW ALZHEIMER'S-ASSOCIATED DISEASE MECHANISMS LIKE NEUROINFLAMMATION AND ACCUMULATION OF A-BETA PROTEIN AFFECT LIPID METABOLISM IN ASTROCYTES AND HOW THESE ASTROCYTE LIPIDS ALTER NEURONAL FUNCTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023008F NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTH FLORIDA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ARI SUDWARTS, PHD, ENTITLED: (A2023009F) IDENTIFYING THE INTERACTOME AND NON-AUTONOMOUS SIGNALLING OF RISK-GENE BIN1 IN AMYLOID-RESPONSIVE MICROGLIA. INVESTIGATOR'S SUMMARY: GENES EXPRESSED IN MICROGLIA - THE IMMUNE CELL OF THE BRAIN - HAVE COME TO LIGHT AS KEY RISK FACTORS FOR LATE-ONSET ALZHEIMER'S DISEASE (LOAD). THE BIN1 GENE CONTAINS THE SECOND-MOST COMMON RISK FOR LOAD, AND BIN1 IS INTEGRAL FOR MICROGLIAL RESPONSES TO INFLAMMATION AND DISEASE. MY PROJECT WILL IDENTIFY WHICH GENES BIN1 INTERACTS WITH IN MICROGLIA, PROVIDING CRUCIAL INSIGHT INTO BIN1 FUNCTION. ADDITIONALLY, I FOUND BIN1 IS INVOLVED IN MICROGLIA SIGNALLING TO OTHER CELLS. THIS WILL BE EXPLORED USING A COMBINATION OF CUTTING-EDGE TECHNOLOGIES TO IDENTIFY CELL RECIPIENTS OF MICROGLIAL SIGNALS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023009F NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, LOS ANGELES. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAVID BOYER, PHD, ENTITLED: (A2023010F) ATOMIC STRUCTURE DETERMINATION OF A-BETA OLIGOMERS ASSOCIATED WITH ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE FORMATION OF AMYLOID FIBRILS IN THE BRAINS OF PATIENTS IS THE DEFINING CHARACTERISTIC OF ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD). EXPERIMENTS DETAILING THE STRUCTURES OF AMYLOID FIBRILS HAVE GREATLY ADVANCED OUR UNDERSTANDING OF ADRD AND OFFER ROUTES TO THERAPEUTIC DEVELOPMENT; HOWEVER, WE ARE CURRENTLY HINDERED IN THE FIGHT TO CURE ADRD DUE TO THE LACK OF STRUCTURES OF INTERMEDIATES ON THE PATHWAY TO FIBRILS - TERMED AMYLOID OLIGOMERS. HERE I PROPOSE TO OBTAIN THE STRUCTURES OF AMYLOID OLIGOMERS USING CRYO-ELECTRON MICROSCOPY TO DEEPEN OUR KNOWLEDGE OF THE MOLECULAR BASIS OF ADRD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023010F
SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:	NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JINGYUAN CHEN, PHD, ENTITLED: (A2023011S) WHOLE-BRAIN SLEEP-WAKE ENERGETICS IN SUBJECTS AT GENETIC RISK FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: RECENT RODENT STUDIES HAVE SUGGESTED THAT DISRUPTED SYNAPTIC ACTIVITY ACROSS SLEEP-WAKE CYCLES PLAYS AN IMPORTANT ROLE IN CAUSING ALZHEIMER'S DISEASE (AD). IN THIS PROPOSAL, WE WILL LEVERAGE CUTTING-EDGE HUMAN IMAGING TECHNIQUES TO TEST WHETHER SUCH ABNORMALITIES OF CYCLIC NEURONAL ACTIVITY ACROSS SLEEP-WAKE CYCLES CAN BE IDENTIFIED IN SUBJECTS AT GENETIC RISK FOR AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023011S NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ARUN UPADHYAY, PHD, ENTITLED: (A2023013F) STABLE ISOTOPE-BASED DATING OF THE AMYLOID FIBRIL PROTEOME. INVESTIGATOR'S SUMMARY: THE RECENT SUCCESS OF ANTIBODY-BASED THERAPEUTICS TARGETING VARIOUS FORMS OF A-BETA PEPTIDES HIGHLIGHTS THE IMPORTANCE OF AMYLOID FIBRILS IN AD PATHOLOGY. NOTABLY, FIBRIL DYNAMICS IS ONE OF THE MOST CRUCIAL FACTORS AFFECTING AMYLOID DEPOSITION DURING AD PROGRESSION. IN THIS APPLICATION, I PROPOSE TO (1) IDENTIFY PROTEINS ASSOCIATED WITH NEWLY FORMED AMYLOID FIBRILS IN THE BRAIN; (2) INVESTIGATE IF MANIPULATING THESE PROTEINS INFLUENCES THE ONSET OF AMYLOID PATHOLOGY. ULTIMATELY, THIS PROJECT WILL UNCOVER NEW ASPECTS OF AMYLOID KINETICS AND MAY PROVIDE NEW TARGETS FOR REDUCING AMYLOID PATHOLOGY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023013F NAME OF ORGANIZATION OR GOVERNMENT: WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SUNG JI AHN, PHD, ENTITLED: (A2023014F) NEUROVASCULAR AND NEURONAL NETWORK DYSFUNCTION IN TAUOPATHY MOUSE MODELS. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS THE LEADING CAUSES OF DEMENTIA, CURRENTLY UNTREATABLE. A MAJOR CULPRIT THAT DAMAGES THE BRAIN IN AD IS THE PROTEIN "TAU." TAU MOLECULES ARE NORMAL CONSTITUENTS OF BRAIN CELLS BUT WHEN CHEMICALLY ALTERED FORM CLUMPS THAT CLOG UP IN THE CELLS. WE SEEK TO FIND OUT IF TAU CLUMPS ARE DAMAGING BY STARVING THE BRAIN OF ITS BLOOD SUPPLY, WHICH CARRIES VITAL OXYGEN AND NUTRIENTS NECESSARY FOR NORMAL BRAIN FUNCTION AND SURVIVAL. WE WILL ALSO TEST IF PROVIDING EXTRA OXYGEN TO THE BRAIN CAN OVERCOME THE BRAIN DYSFUNCTION CAUSED BY TAU, WHICH COULD HAVE THERAPEUTIC IMPLICATIONS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023014F NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ALYSSA COYNE, PHD, ENTITLED: (A2023015S) ESCRT-III NUCLEAR SURVEILLANCE IN CHMP2B FTD. INVESTIGATOR'S SUMMARY: MAINTENANCE OF THE PROTEIN COMPLEXES THAT CONTROL COMMUNICATION BETWEEN THE NUCLEAR AND CYTOPLASMIC COMPARTMENTS OF CELLS IS ESSENTIAL FOR PROPER NEURONAL FUNCTION AND SURVIVAL. RECENT WORK HAS DEMONSTRATED THAT DEFECTS IN A NUCLEAR SURVEILLANCE PATHWAY INITIATE DAMAGE TO THESE CELLULAR COMMUNICATION CHANNELS AS AN EARLY AND SIGNIFICANT EVENT IN LOU GEHRIG'S DISEASE. THIS PROPOSAL WILL EXAMINE THE CONTRIBUTION OF IMPAIRED NUCLEAR SURVEILLANCE AND NUCLEAR-CYTOPLASMIC COMPARTMENTALIZATION TO A GENETICALLY LINKED FORM OF DEMENTIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023015S NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTHERN CALIFORNIA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PAUL SEIDLER, PHD, ENTITLED: (A2023016S) UNFOLDING ALZHEIMER'S TAU THERAPIES: APPROACHES FOR THE NEAR- AND LONG-TERM. INVESTIGATOR'S SUMMARY: BY NO MISTAKE, NATURAL PRODUCT CHEMICALS IN THE FORMS OF VITAMINS AND DIETARY SUPPLEMENTS HAVE LONG PLAYED A ROLE IN SUPPORTING HUMAN HEALTH. IN THE CONTEXT OF AGING, PLANT NATURAL PRODUCTS EVOLVED ALONGSIDE MICROBIAL PROTEINS THAT BEAR STRUCTURAL SIMILARITY TO PROTEINS FROM THE HUMAN BRAIN THAT BECOME TANGLED WITH AGE. WE LEVERAGE THESE REALIZED STRUCTURAL AND CHEMICAL SIMILARITIES TO DEVELOP DIETARY SUPPLEMENTS AND PHARMACEUTICAL-GRADE MEDICINES TO SUPPORT HEALTHIER AGING AND TO TREAT AD, RESPECTIVELY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023016S NAME OF ORGANIZATION OR GOVERNMENT: SHRINERS HOSPITALS FOR CHILDREN - NORTHERN CALIFORNIA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY OLGA CHECHNEVA, PHD, ENTITLED: (A2023017S) NUCLEAR MATERIAL TRANSFER IN PATHOGENIC PROTEIN SPREADING. INVESTIGATOR'S SUMMARY: SPREADING OF PATHOGENIC PROTEIN AGGREGATES IN NEURONS CAUSES PROGRESSION OF ALZHEIMER'S DISEASE AND MANY GENETIC AND AGE-RELATED NEUROLOGICAL DISORDERS. THIS PROJECT WILL INVESTIGATE A PREVIOUSLY UNRECOGNIZED POPULATION OF SOX-10 LINEAGE CELLS THAT TRANSFER NUCLEAR AND RIBOSOMAL MATERIAL TO NEURONS AND THEIR ROLE IN PATHOGENIC PROTEIN SPREADING. OUR RESEARCH WILL ADVANCE OUR UNDERSTANDING OF THE MECHANISMS UNDERLYING PATHOGENIC PROTEIN SPREADING WITH THE AIM TO DEVELOP NOVEL THERAPIES TO TREAT ALZHEIMER'S DISEASE AND OTHER DEVASTATING DISORDERS OF THE NERVOUS SYSTEM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023017S NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HENRY PAN, PHD, ENTITLED: (A2023019F) FIDELITY OF TAU STRAIN TRANSMISSION: A FLUORESCENCE IN SITU AND CRYO-EM STRUCTURAL CHARACTERIZATION STUDY. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE AND ALZHEIMER'S RELATED DISEASES (ADRD) ARE PROTEIN CONFORMATIONAL DISEASES, WHERE THE SAME PROTEIN SUCH AS TAU CAN TAKE ON A DIVERSE RANGE OF CONFORMATIONAL STRAINS EACH ONE ASSOCIATED WITH A DIFFERENT DISEASE. MODELING TAU STRAINS CORRECTLY IS IMPORTANT FOR MECHANISTIC BIOLOGICAL STUDIES AND PRECLINICAL DRUG DEVELOPMENT STUDIES. THIS PROPOSAL SEEKS TO DEVELOP METHODS THAT CAN RAPIDLY SCREEN FOR FIBRIL STRAINS IN CELL AND TRANSGENIC RODENT MODELS TO ISOLATE STRAINS OF INTEREST FROM HETEROGENEOUS SAMPLES FOR CRYO-EM STRUCTURAL CHARACTERIZATION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023019F NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KENTUCKY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KATE FOLEY, PHD, ENTITLED: (A2023020F) DETERMINING THE MECHANISMS OF ANTI-A-BETA IMMUNOTHERAPY ON CEREBROVASCULAR DYSFUNCTION. INVESTIGATOR'S SUMMARY: WITH RECENT FDA APPROVAL OF ANTI-A-BETA IMMUNOTHERAPIES TO TREAT ALZHEIMER'S DISEASE, IT IS IMPERATIVE TO UNDERSTAND HOW TO MITIGATE THE CEREBROVASCULAR SIDE EFFECTS CAUSED BY THESE THERAPIES. THIS PROPOSAL WILL CHARACTERIZE THE CELLULAR RESPONSE TO ANTI-A-BETA ANTIBODY TREATMENT, AS WELL AS DETERMINE THE ROLE OF A VASCULAR DAMAGING PROTEIN, MMP9, IN PREVENTING THE CEREBROVASCULAR DEFICITS THAT RESULT FROM ANTI-A-BETA ANTIBODY THERAPY. THIS PROJECT WILL IDENTIFY TARGETABLE PATHWAYS TO HELP REDUCE CEREBROVASCULAR ADVERSE EVENTS ASSOCIATED WITH ANTI-A-BETA IMMUNOTHERAPIES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023020F NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARIA VIRTUDES SANCHEZ MICO, PHD, ENTITLED: (A2023021F) IN VIVO IMAGING OF ASTROGLIAL DYSFUNCTION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ASTROCYTES PLAY AN ESSENTIAL METABOLIC ROLE TO SUPPORT ENERGY REQUIREMENTS OF BRAIN CELLS. IMPAIRMENT OF ASTROGLIAL METABOLISM IS THOUGHT TO ACCELERATE NEURONAL DEGENERATION AND WORSEN ALZHEIMER'S DISEASE (AD). THUS, THERE IS AN URGENT NEED TO FULLY UNDERSTAND ASTROGLIAL METABOLIC DYSFUNCTION. HERE, WE WILL IMAGE THE ASTROGLIAL METABOLISM IN THE BRAINS OF LIVING AD MOUSE MODEL USING FLUORESCENT REPORTER MOLECULES AND MULTIPHOTON MICROSCOPY. THE OUTCOME OF OUR EXPERIMENTS WOULD FACILITATE THE DEVELOPMENT OF NEW THERAPEUTIC STRATEGIES TO PREVENT OR REVERSE THE PROGRESSION OF THIS DEVASTATING DISEASE FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023021F
SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:	NAME OF ORGANIZATION OR GOVERNMENT: YALE UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CARLA ROTHLIN, PHD, ENTITLED: (A2023022S) FUNCTIONAL UNDERSTANDING OF AXL EFFECTOR ROLE(S) IN MICROGLIA TOWARDS DEVELOPING DISEASE MODIFYING THERAPIES IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: WE HAVE IDENTIFIED A PROTEIN EXPRESSED IN BRAIN IMMUNE CELLS THAT MAKES THESE CELLS BETTER AT PROTECTING AGAINST ALZHEIMER'S DISEASE (AD). HERE WE ENVISION TO UNDERSTAND EXACTLY HOW THIS PROTEIN FUNCTIONS BY ENGULFING AND REMOVING A-BETA PLAQUES OR BY DAMPENING INFLAMMATION TO PREVENT AD-ASSOCIATED NEUROINFLAMMATION. WE WILL ALSO BETTER UNDERSTAND THE SEQUENCE OF EVENTS LEADING TO THE IMPROVED ACTIVITY OF THIS PROTEIN THAT PROTECTS AGAINST COGNITIVE DECLINE. THIS KNOWLEDGE WILL ENABLE US TO DEVELOP THERAPEUTICS TO IMPROVE DISEASE OUTCOME IN AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023022S NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SUBHOJIT ROY, MD, PHD, ENTITLED: (A2023023S) THERAPEUTIC GENE-EDITING IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: OUR OVERALL GOAL IS TO TAKE A CRISPR BASED GENE THERAPY FOR ALZHEIMER'S DISEASE (AD) TO THE CLINIC. BROADLY SPEAKING, OUR APPROACH RESTORES THE PHYSIOLOGIC BALANCE OF THE AMYLOID PATHWAY DECREASING NEUROTOXIC PROTEIN FRAGMENTS, WHILE PROMOTING NEUROPROTECTIVE PROTEIN FRAGMENTS. THERE ARE OVER 100 ONGOING CLINICAL TRIALS WORLDWIDE USING CRISPRS, AND THE RESULTS SO FAR WITH NON-NEUROLOGIC DISORDERS HAVE SHOWN UNPRECEDENTED (ALMOST 100%) EFFICACY. OUR BROAD VISION IS TO APPLY CRISPRS FOR DEVASTATING NEUROLOGIC ILLNESSES LIKE AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023023S NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KENTUCKY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DANIEL C. LEE, PHD, ENTITLED: (A2023025S) CITRULLINATED TAU AS A THERAPEUTIC TARGET IN TAUOPATHIES. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) CONTINUES TO IMPACT NEURONAL HEALTH. TAU PATHOLOGY IS DIVERSE DESPITE BEING A SINGLE PROTEIN AND ALSO REMAINS THE CLOSET COROLLARY TO MEMORY LOSS AND NEURODEGENERATION. TAU DIVERSITY LIKELY COMES FROM DIFFERENT CELLULAR MODIFICATIONS ON THE TAU PROTEIN. WE DISCOVERED A NEW MODIFICATION ON TAU CALLED CITRULLINATION WHICH CHANGES THE AMINO ACID ARGININE TO A CITRULLINE. WE HYPOTHESIZE THAT CITRULLINATION TO TAU CAUSES MORE TOXICITY IN THE BRAIN. WE WILL TEST CITRULLINATION INHIBITORS AND VACCINES AGAINST CITRULLINATED TAU IN MICE THAT DEVELOP HALLMARKS OF AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2023025S NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC, JACKSONVILLE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ENTITLED: (CA2021010) MOLECULAR NEURODEGENERATION JOURNAL. INVESTIGATOR'S SUMMARY: THE AIM OF MOLECULAR NEURODEGENERATION (MN) JOURNAL (HTTPS://MOLECULARNEURODEGENERATION.BIOMEDCENTRAL.COM/) IS TO SERVE THE SCIENTIFIC COMMUNITY BY PUBLISHING HIGH-IMPACT, HIGH-QUALITY, AND FRONT-LINE RESEARCH DISCOVERIES IN DIVERSE AREAS OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE AND EYE-RELATED DEGENERATIVE CONDITIONS. MN IS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION. ALL ARTICLES ARE FREE AND PERMANENTLY ACCESSIBLE ONLINE, WITHOUT SUBSCRIPTION CHARGES OR REGISTRATION BARRIERS. THE JOURNAL HAS SEEN FURTHER GROWTH IN RECENT YEARS IN PARTICULAR IN THE AREA OF SCIENTIFIC IMPACT AND REPUTATION. SOME OF THESE ARE REFLECTED IN THE FOLLOWING METRICS: 1) THE IMPACT FACTOR OF MOLECULAR NEURODEGENERATION, THE OFFICIAL SCIENTIFIC JOURNAL OF BRIGHTFOCUS FOUNDATION, HAS RISEN TO 18.879, ACCORDING TO ITS PUBLISHER, UP FROM 14.195 A YEAR AGO (33% INCREASE).; 2) IT IS NOW THE TOP-RANKED OPEN-ACCESS PUBLICATION IN ITS FIELD, ON PAR WITH OTHER HIGH-IMPACT JOURNALS INCLUDING NEURON, JOURNAL OF EXPERIMENTAL MEDICINE AND NATURE COMMUNICATIONS. A SCIENTIFIC JOURNAL'S IMPACT FACTOR IS DERIVED FROM HOW OFTEN ITS ARTICLES ARE CITED IN SCIENTIFIC LITERATURE DURING A PARTICULAR TIME PERIOD AND REFLECTS THE JOURNAL'S INFLUENCE IN SHAPING AND LEADING SCIENTIFIC PROGRESS. JOURNALS WITH HIGHER IMPACT FACTORS ARE CONSIDERED MORE PRESTIGIOUS AND HAVE HIGHER STANDARDS FOR PUBLICATION.; 3) THE JOURNALHAS BEEN RANKED AS THENUMBER ONE OPEN-ACCESS JOURNALIN THE NEUROSCIENCE CATEGORY FOR NINE YEARS IN A ROW (2013 PRESENT) AND IS RANKED NO. 7 AMONGALL274 NEUROSCIENCE JOURNALS. AMONG THE TOP 10, MOLECULAR NEURODEGENERATION IS THE ONLY OPEN-ACCESS JOURNAL. NAME OF ORGANIZATION OR GOVERNMENT: LUMIND IDSC. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: MODELING THE IMPACT OF RESEARCH INVESTMENT ON ALZHEIMER'S DISEASE IN DOWN SYNDROME: CAREGIVING AND SOCIETAL COSTS. NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE. NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ENTITLED: (CA2021011) MOLECULAR NEURODEGENERATION JOURNAL. INVESTIGATOR'S SUMMARY: THIS AWARD IS FOR THE CREATION, AND GROWTH OF, THE "INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (ISMND) AND SUPPORT OF ITS BI-ANNUAL MEETINGS AND EDUCATIONAL AND SCIENTIFIC PURPOSES. IN ACCORDANCE WITH SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND THE PROVISIONS OF THE FLORIDA NOT FOR PROFIT CORPORATION ACT. THE INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (ISMND) SHALL BE ORGANIZED AND OPERATED PRIMARILY AND EXCLUSIVELY FOR EDUCATIONAL AND SCIENTIFIC PURPOSES. THE INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION'S MISSION IS TO SERVE AS AN ACCELERATOR FOR THE CONTINUOUS IMPROVEMENT OF BRAIN AND EYE HEALTH AND WELL-BEING BY CREATING A MULTIDISCIPLINARY GLOBAL PLATFORM FOR SCIENTISTS, PHYSICIANS, AND THE PUBLIC FROM DIFFERENT FACETS AND SCIENTIFIC DISCIPLINES TO MORE READILY CONNECT, SHARE AND COMMUNICATE SCIENTIFIC DISCOVERIES, AND DEVELOP CURES FOR NEURODEGENERATIVE DISEASES, IN THE HOPES OF A WORLD FREE OF BRAIN AND EYE DISEASES. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE. NAME OF ORGANIZATION OR GOVERNMENT: FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SJOERD FINNEMA, PHD, ENTITLED: (CA2021012) SV2A PET AS A BIOMARKER OF SYNAPTIC DENSITY. INVESTIGATOR'S SUMMARY: THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH (FNIH) BIOMARKERS CONSORTIUM (BC) HAS LAUNCHED A PROJECT THAT SIGNALS A PARADIGM SHIFT IN OUR METHODS TO IMAGE THE BRAIN. USING ADVANCES IN PET (POSITRON EMISSION TOPOGRAPHY) TECHNOLOGY, THE PROJECT WILL FOCUS ON MEASURING THE INTEGRITY OF SYNAPSESTINY GAPS THAT CONNECT NEURONS AND COMMUNICATE INFORMATION TO THE BRAIN. LOSS OF THESE SYNAPSE CONNECTIONS STRONGLY CORRELATES WITH COGNITIVE DECLINE IN ALZHEIMER'S DISEASE (AD). A NEW IMAGING TOOL TO TRACK THIS BIOLOGICAL INDICATOR OF DISEASE PROGRESSION AND OF PATIENT RESPONSE TO THERAPEUTIC INTERVENTIONS WOULD BE A CATALYST IN THE DEVELOPMENT OF CLINICALLY EFFECTIVE TREATMENTS FOR AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2021012
SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:	NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF COLORADO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LOTTA GRANHOLM, PHD, ENTITLED: (CA2018010) INTERNATIONAL BRAIN BANK FOR DOWN SYNDROME-RELATED ALZHEIMER'S DISEASE. EMERGENCY RELIEF SUPPLEMENT DUE TO COVID-19. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2018010 NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTHERN CALIFORNIA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JINKOOK LEE, PHD, ENTITLED: (CA2023001) EXPANDING AND ENHANCING LASI-DAD FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE AND DEMENTIA. INVESTIGATOR'S SUMMARY: THIS PROJECT WILL EXPAND AND ENHANCE THE ONGOING LONGITUDINAL AGING STUDY IN INDIA DIAGNOSTIC ASSESSMENT OF DEMENTIA (LASI-DAD) BY EXPLORING HOW DNA METHYLATION OF ALZHEIMER'S ASSOCIATED GENES IS ASSOCIATED WITH COGNITION AND DEMENTIA. IT WILL FURTHER VALIDATE PREVIOUS FINDINGS FROM THE LASI-DAD TO COMPARE THE ACCURACY OF FINDINGS WITH GOLD STANDARD MEASURES OF COGNITION AND BLOOD BIOMARKERS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2023001 NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, BERKELEY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SHUBHAM MAURYA, PHD, ENTITLED: (G2023001F) REGULATION OF MICROGLIAL PHENOTYPE BY NEUROPROTECTIVE LXB4 IN OCULAR HYPERTENSION-INDUCED NEUROPATHY. INVESTIGATOR'S SUMMARY: WE HAD IDENTIFIED A NOVEL WAY TO STOP THE DEATH OF RETINAL CELLS IN MICE GLAUCOMATOUS EYES USING SMALL MOLECULE LIPID MEDIATORS. THESE LIPID MEDIATORS HAVE BIOACTIONS IN MODULATING THE FUNCTIONS OF A RESIDENT IMMUNE CELL TYPE IN THE RETINA, I.E., MICROGLIA. THIS PROJECT INTENDS TO STUDY THE REGULATION OF MICROGLIA BY LIPIDS MEDIATORS DURING GLAUCOMA PROGRESSION TO STOP OR PREVENT THE DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023001F NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KAZUYA OIKAWA, PHD, BVSC, ENTITLED: (G2023003F) MODULATION OF NEUROINFLAMMATION IN GLAUCOMA BY GLP-1R AGONIST. INVESTIGATOR'S SUMMARY: INFLAMMATION OF THE NERVOUS SYSTEM TISSUE CONTRIBUTES TO BLINDING LOSS OF NERVE CELLS IN THE EYE AND BRAIN IN GLAUCOMA. IN THIS PROJECT, WE AIM TO REPURPOSE AN EXISTING FDA-APPROVED DRUG TO MODIFY THIS INFLAMMATORY RESPONSE WITH THE GOAL OF IDENTIFYING A POTENTIAL NEW THERAPY TO HELP PRESERVE VISION IN PATIENTS WITH GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023003F NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, BERKELEY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KARTHIK SHEKHAR, PHD, ENTITLED: (G2023004S) A SPATIAL TRANSCRIPTOMICS APPROACH TO IDENTIFY MOLECULAR CHANGES AND MULTICELLULAR INTERACTIONS UNDERLYING RETINAL NEURODEGENERATION IN GLAUCOMA. INVESTIGATOR'S SUMMARY: TO IDENTIFY NOVEL MOLECULAR TARGETS THAT CAN SLOW DOWN RELENTLESS RETINAL GANGLION CELL (RGC) DEATH IN GLAUCOMA, WE NEED TO UNDERSTAND MOLECULAR PATHWAYS AND MULTI-CELLULAR INTERACTIONS THAT UNDERLIE RGC SUSCEPTIBILITY. WE WILL COMBINE INNOVATIVE SPATIAL PROFILING TECHNOLOGIES, MOUSE MODELS, AND MACHINE LEARNING TO UNDERSTAND RGC DEGENERATION AND THE ROLE OF THE MICROENVIRONMENT IN GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023004S NAME OF ORGANIZATION OR GOVERNMENT: GEORGIA TECH RESEARCH CORPORATION. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MARK PRAUSNITZ, PHD, ENTITLED: (G2023007S) NON-DRUG, NON-SURGICAL HYDROGEL-BASED TREATMENT OF GLAUCOMA. INVESTIGATOR'S SUMMARY: REDUCING INTRAOCULAR PRESSURE (IOP) IS THE ONLY GLAUCOMA TREATMENT, BUT IS OFTEN INEFFECTIVE DUE TO POOR PATIENT COMPLIANCE AND SURGICAL COMPLICATIONS. WE DEVELOPED A NON-DRUG, NON-SURGICAL METHOD TO LOWER IOP BY INJECTING A HYDROGEL TO EXPAND THE SUPRACHOROIDAL SPACE OF THE EYE. HERE WE OPTIMIZE THE HYDROGEL TO PROLONG IOP LOWERING, EVALUATE ITS SAFETY AND EFFICACY AND STUDY MECHANISMS OF ACTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023007S NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY RUPALATHA MADDALA, PHD, ENTITLED: (G2023008S) ROLE OF SEPTIN CYTOSKELETON IN TRABECULAR MESHWORK, IOP AND GLAUCOMA. INVESTIGATOR'S SUMMARY: STUDIES DESCRIBED IN THIS PROPOSAL ARE FOCUSED ON INVESTIGATING THE ROLE OF SEPTINS WHICH ARE IDENTIFIED AS THE RISK LOCI FOR OCULAR HYPERTENSION AND GLAUCOMA IN THE HOMEOSTASIS OF AQUEOUS HUMOR OUTFLOW AND INTRAOCULAR PRESSURE. AS WE LACK AN UNDERSTANDING OF HOW SEPTINS MAY INFLUENCE OCULAR PRESSURE, COMPLETION OF THE STUDIES PLANED IN THIS APPLICATION ARE EXPECTED TO SHED LIGHT ON THIS QUESTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023008S NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY, INDIANAPOLIS. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY WEIMING MAO, PHD, ENTITLED: (G2023009S) A NOVEL MOUSE ANTERIOR SEGMENT PERFUSION CULTURE MODEL FOR MEASURING OUTFLOW FACILITY AND LONG-TERM PERFUSION CULTURE. INVESTIGATOR'S SUMMARY: GLAUCOMA IS A LEADING CAUSE OF BLINDNESS. THE MOST IMPORTANT RISK FACTOR OF GLAUCOMA IS HIGH PRESSURE INSIDE THE EYE. THIS PRESSURE ELEVATION IS DUE TO HIGH DRAINAGE RESISTANCE OF THE FLUID THAT FILLS THE EYE. TO BETTER UNDERSTAND THIS PRESSURE ELEVATION, LAB MICE HAVE BEEN WIDELY USED AS A RESEARCH MODEL. WE WILL DEVELOP A NOVEL METHOD TO MEASURE THIS DRAINAGE RESISTANCE IN MOUSE EYES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023009S NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JITHIN YOHANNAN, MD, ENTITLED: (G2023010S) DEVELOPING DEEP LEARNING APPROACHES TO REDUCE THE BURDEN OF GLAUCOMA CLINICAL TRIALS. INVESTIGATOR'S SUMMARY: CLINICAL TRIALS OF NEW GLAUCOMA DRUGS (NEUROPROTECTIVE AGENTS) ARE DIFFICULT BECAUSE THE WORSENING OF GLAUCOMA MUST BE TRACKED WITH VISUAL FIELD TESTING, WHICH IS VARIABLE AND ONEROUS. IN THIS PROPOSAL, WE DEVELOP AI MODELS THAT WILL REDUCE TRIAL TIME, COST, AND BURDEN BY 1) IDENTIFYING THE BEST CANDIDATES TO ENROLL IN TRIALS AND 2) USING DATA BEYOND THE VISUAL FIELD TO DETECT WORSENING. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2023010S
SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:	NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR EYE RESEARCH. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH TRAVEL GRANTS FOR CONFERENCE ATTENDANCE. NAME OF ORGANIZATION OR GOVERNMENT: GEORGIA INSTITUTE OF TECHNOLOGY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY C. ROSS ETHIER, PHD, ENTITLED: (CG2020001) SELECTIVE TARGETING OF SCHLEMM'S CANAL INNER WALL FOR NEXT-GENERATION GLAUCOMA DRUGS: SUBPART A. INVESTIGATOR'S SUMMARY: ALL TREATMENTS FOR GLAUCOMA SEEK TO LOWER INTRAOCULAR PRESSURE (IOP), YET EXISTING APPROACHES ARE INSUFFICIENT. WE NOW UNDERSTAND THAT ENDOTHELIAL CELL OF THE INNER WALL OF SCHLEMM'S CANAL (SC) PLAY A KEY ROLE IN HOMEOSTATIC CONTROL MECHANISMS THAT MAINTAIN IOP WITHIN A TARGET RANGE. HOWEVER, TOOLS FOR DIRECTLY ASSESSING SC INNER WALL ENDOTHELIAL FUNCTION ARE LACKING, AS ARE MOLECULAR APPROACHES FOR DIRECTLY TARGETING AND INTERROGATING THESE CELLS. THE LONG-TERM GOAL OF THIS INTER-DEPENDENT, MULTIPLE PRINCIPAL INVESTIGATOR AND GRANTEE INSTITUTION-ASSOCIATED PROJECT IS TO DEVELOP NOVEL THERAPIES THAT DIRECTLY TARGET SC CELLS TO IMPROVE IOP CONTROL. THESE TARGETED THERAPIES WILL BE HIGHLY EFFECTIVE DUE THEIR SPECIFICITY, AND WILL THUS GREATLY BENEFIT GLAUCOMA PATIENTS. TO ACCOMPLISH THIS GOAL, WE HAVE ASSEMBLED AN OUTSTANDING TEAM THAT BRINGS TOGETHER ALL NECESSARY EXPERTISE TO INTERVENE IN THIS COMPLEX SYSTEM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CG2020001 NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY W. DANIEL STAMER, PHD, ENTITLED: (CG2020002) SELECTIVE TARGETING OF SCHLEMM'S CANAL INNER WALL FOR NEXT-GENERATION GLAUCOMA DRUGS: SUBPART B. INVESTIGATOR'S SUMMARY: FOR THE PROJECT, WE WILL SCREEN CANDIDATE ADENO ASSOCIATED VIRUSES AND ENGINEERED PROMOTERS CLONED INTO LENTIVIRUSES OBTAINED FROM COLLABORATORS IN HUMAN SCHLEMM'S CANAL CELLS IN VITRO AND ANTERIOR SEGMENTS EX VIVO FOR SELECTIVE TROPISM TO/ACTIVITY IN TRABECULAR MESHWORK VERSUS SCHLEMM'S CANAL. WE WILL UTILIZE RECENTLY VALIDATED VIRUS TECHNOLOGY (ENOS PROMOTERS DRIVING XFP OR SEAP REPORTER PROTEINS) TO TRANSDUCE SCHLEMM'S CANAL IN HUMAN ANTERIOR SEGMENTS AND MONITOR SHEAR STRESS LEVELS AND LOCATION THROUGHOUT SCHLEMM'S CANAL. WE WILL PROVIDE A STEADY SUPPLY OF SCHLEMM'S CANAL CELLS FOR DEVELOPMENT AND TESTING OF DRUG SCREENING PLATFORMS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CG2020002 NAME OF ORGANIZATION OR GOVERNMENT: COLUMBIA UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SIMON JOHN, PHD, ENTITLED: (CG2020004) SELECTIVE TARGETING OF SCHLEMM'S CANAL INNER WALL FOR NEXT-GENERATION GLAUCOMA DRUGS: SUBPART D. INVESTIGATOR'S SUMMARY: THE PROJECT AIMS TO DEVELOP AND TEST RESOURCES FOR SCHLEMM'S CANAL SPECIFIC TARGETING AND EXPRESSION OF GENES FOR GENE THERAPY. SUCCESSFUL DEVELOPMENT OF THIS TARGETED THERAPY WILL HELP CONTROL EYE PRESSURE MORE EFFECTIVELY AND PROVIDE BETTER TREATMENT OPTIONS FOR GLAUCOMA PATIENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CG2020004 NAME OF ORGANIZATION OR GOVERNMENT: STANFORD UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG, PHD, ENTITLED: (CG2022001) A RANDOMIZED, SHAM CONTROLLED, MASKED PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUAL INTRAVITREAL IMPLANTATION OF NEUROPROTECTIVE CELL THERAPY FOR THE TREATMENT OF GLAUCOMA. INVESTIGATOR'S SUMMARY: THE PROPOSED PROJECT IS AN EXTENSION OF THE CURRENT PHASE 2 CLINICAL TRIAL, TO ASSESS AND VALIDATE THE USE OF DUAL NT-501 CNTF ENCAPSULATED CELL THERAPY (ECT) ON VISUAL IMPAIRMENT RELATED TO GLAUCOMA, IN HUMAN SUBJECTS. THE PROPOSED STUDY IS DESIGNED TO EXPAND OUR KNOWLEDGE OF THE DOSE-DEPENDENT EFFECT OF CNTF IN GLAUCOMA THROUGH DUAL IMPLANTATION OF NT-501 ECT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CG2022001 NAME OF ORGANIZATION OR GOVERNMENT: THE JACKSON LABORATORY. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY NAVDEEP GOGNA, PHD, ENTITLED: (M2023001F) MITOCHONDRIAL DYSFUNCTION AS A KEY MEDIATOR OF AMD-LIKE PHENOTYPES IN HUMANIZED ARMS2A69S MICE. INVESTIGATOR'S SUMMARY: VARIATIONS IN THE PRIMATE SPECIFIC GENE ARMS2 ARE IMPLICATED IN AGE-RELATED MACULAR DEGENERATION (AMD). HOWEVER, THE MECHANISMS BY WHICH ARMS2 INCREASES AMD RISK ARE NOT KNOWN. THE NISHINA LAB HAS DEVELOPED NEW HUMANIZED MOUSE MODELS TO STUDY THE ROLE OF ARMS2 IN AMD. PRELIMINARY RESULTS SUGGEST EARLY CHANGES IN MITOCHONDRIAL GENES, ALTERED LIPID METABOLISM AND AGE-ASSOCIATED AMD-LIKE PHENOTYPES IN THE MODEL. THIS STUDY WILL IDENTIFY ALTERATIONS IN MITOCHONDRIA AND LIPID METABOLISM DUE TO ARMS2A69S RISK VARIANT, IN AMD DEVELOPMENT, THAT COULD BE TARGETED FOR THERAPEUTIC BENEFIT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023001F NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PENNSYLVANIA. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY CATHARINA GRUBAUGH, PHD, ENTITLED: (M2023002F) MICROSOMAL TRANSFER PROTEIN IN RETINAL LIPID HOMEOSTASIS, IMPLICATIONS FOR AMD. INVESTIGATOR'S SUMMARY: RECENT RESEARCH HAS INCREASINGLY LINKED AGE-RELATED MACULAR DEGENERATION (AMD) TO LIPID DYSREGULATION IN THE EYE. ONE OF THE MOST IMPORTANT ROLES OF THE RETINAL PIGMENT EPITHELIUM (RPE) IS THE PROCESSING AND TRANSPORT OF LIPIDS. MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP), ENCODED BY THE MTTP GENE, REGULATES LIPID PACKAGING IN THE RPE. WE HAVE GENERATED THE RPEDELMTTP MOUSE, IN WHICH MTTP IS KNOCKED OUT IN THE RPE BUT EXPRESSED NORMALLY IN OTHER TISSUES. WE WILL TEST THE HYPOTHESIS THAT MTP-MEDIATED LIPID PACKAGING IN THE RPE IS NECESSARY TO MAINTAIN RETINAL HEALTH AND VISUAL FUNCTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023002F NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JACLYN SWAN, PHD, ENTITLED: (M2023003F) THE GLYCANS OF THE HUMAN RETINA AND THEIR INTERACTION WITH COMPLEMENT FACTOR H. INVESTIGATOR'S SUMMARY: ALL CELLS IN THE HUMAN BODY ARE COVERED IN A COMPLEX SUGAR COAT, THE GLYCOCALYX. THIS MOLECULAR COAT IS CRUCIAL FOR CELL-TO-CELL COMMUNICATION AND IMMUNE SURVEILLANCE. AN UNDERLYING MECHANISM OF AGE-RELATED MACULAR DEGENERATION (AMD) IS THE DYSREGULATION OF THE INNATE IMMUNE SYSTEM. THE GLYCOCALYX IS INVOLVED IN REGULATING THESE SYSTEMS. CURRENTLY, WE DON'T KNOW THE PRECISE COMPOSITION OF THE SUGAR COATS ON CELLS IN THE EYE AT THE SITE WHERE AMD OCCURS. WE WILL CHARACTERIZE THE GLYCOCALYX OF DISEASED AND HEALTHY EYES TO TEST WHETHER DIFFERENCES CONTRIBUTE TO IMMUNOLOGICAL CONSEQUENCES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023003F
SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:	NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WASHINGTON. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY RAYNE LIM, PHD, ENTITLED: (M2023004F) FACTOR H-LIKE PROTEIN 1 INSUFFICIENCY IN RETINAL PIGMENT EPITHELIUM. INVESTIGATOR'S SUMMARY: EARLY ONSET MACULAR DRUSEN (EOMD) IS AN INHERITED, SEVERE FORM OF AGE-RELATED MACULAR DEGENERATION (AMD). WE FOUND THAT RETINAL PIGMENTED EPITHELIUM (RPE) CELLS MADE FROM EOMD PATIENTS HAVE DECREASED (ABOUT 50%) EXPRESSION OF TWO IMPORTANT COMPLEMENT PROTEINS, CFH AND FHL-1. THIS SIGNIFICANT DECREASE MAY ALTER LOCAL COMPLEMENT ACTIVITY AND RPE METABOLISM. WE WILL STUDY EOMD PATIENT RPE, THEIR GENE-EDITED CONTROLS, AND DETERMINE WHETHER ADDING THE FHL-1 GENE BACK TO THE EOMD CELLS WILL HELP ATTENUATE THESE PATHOGENIC CHANGES. THIS PROJECT WILL HELP OUR UNDERSTANDING OF AMD DISEASE PATHOGENESIS AND TREATMENT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023004F NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY SANGEETHA KANDOI, PHD, ENTITLED: (M2023005F) PHOTORECEPTOR REMODELING IN THE HIBERNATING CONE-DOMINANT 13-LINED GROUND SQUIRREL AS A MODEL FOR MACULAR DEGENERATION IN HUMANS. INVESTIGATOR'S SUMMARY: THE CONE PHOTORECEPTORS EXCLUSIVELY POPULATE THE SMALL CENTRAL REGION WITHIN THE HUMAN RETINA AND PROVIDE HIGH ACUITY, AND COLOR VISION. THE LOSS OF CONES IS AN ENDPOINT OF AGE-RELATED MACULAR DEGENERATION (AMD), THE LEADING CAUSE OF BLINDNESS IN INDIVIDUALS >50 YEARS OLD. OUR STUDY UTILIZES 13-LINED GROUND SQUIRREL (13-LGS), WHICH HAS 85% CONES OVERALL AND HIBERNATES IN WINTER. THE ABUNDANCE OF CONES, AND EVOLVED PROTECTION AGAINST HIBERNATION STRESS ON CONES SUGGEST THAT THE 13-LGS COULD BE A CLINICALLY RELEVANT MODEL FOR EXPLORING INNOVATIVE THERAPIES FOR CATASTROPHIC VISION LOSS IN AMD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023005F NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JAMES WALSH, MD, PHD, ENTITLED: (M2023006F) DYSREGULATED CHOROIDAL ADAPTIVE IMMUNITY EXACERBATES MACULAR DEGENERATION PATHOLOGY. INVESTIGATOR'S SUMMARY: MACULAR DEGENERATION IS ONE OF THE LEADING CAUSES OF BLINDNESS IN THE US, YET THE EXACT DISEASE PROCESS THAT LEADS TO THE FINDINGS OF THIS DISEASE ARE NOT KNOWN. THERE HAVE BEEN CONSISTENT STUDIES THAT SHOW THAT THE ADAPTIVE IMMUNE SYSTEM IS ALTERED SYSTEMICALLY, BUT BECAUSE THE EYE HAS A REPUTATION FOR BEING IMMUNE PRIVILEGED, THE ROLE OF THE LOCAL ADAPTIVE IMMUNE SYSTEM IN THIS PROCESS HAS NOT BEEN EXPLORED. WE RECENTLY DISCOVERED THAT THERE IS A RICH ADAPTIVE LYMPHOID ENVIRONMENT IN THE CHOROID THAT COULD CONTRIBUTE TO THE DISEASE PROCESS, AND WILL EXPLORE THIS FURTHER IN THIS PROPOSAL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023006F NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF IOWA. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY NARENDRA PANDALA, PHD, ENTITLED: (M2023007F) AUTOLOGOUS CHOROIDAL ENDOTHELIAL CELL REPLACEMENT FOR THE TREATMENT OF AMD. INVESTIGATOR'S SUMMARY: AGE RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF BLINDNESS IN THE U.S. IN THE DRY FORM OF THE DISEASE, THE MACULA, WHICH IS THE CENTRAL MOST PART OF THE RETINA THAT IS RESPONSIBLE FOR HIGH ACUITY VISION, DETERIORATES. RECENT STUDIES HAVE SHOWN THAT THE CAPILLARIES PRESENT UNDERNEATH THE RETINA IN THE CHOROID ARE LOST BEFORE RETINAL DEGENERATION. IN THIS PROJECT, WE PROPOSE TO DEVELOP AN EARLY INTERVENTION STRATEGY TO TRANSPLANT PATIENT-DERIVED CHOROIDAL STEM CELLS USING A BIOMATERIAL TO REPOPULATE THE LOST CAPILLARIES IN THE CHOROID AND THUS PREVENT FURTHER DAMAGE TO THE RETINA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023007F NAME OF ORGANIZATION OR GOVERNMENT: OREGON HEALTH & SCIENCE UNIVERSITY. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY YALI JIA, PHD, ENTITLED: (M2023008I) IMAGING CHORIOCAPILLARIS HEMODYNAMIC DEFECTS IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF BLINDNESS. ADVANCED FORMS OF THE DISEASE THAT INCLUDE GEOGRAPHIC ATROPHY REMAIN WITHOUT TREATMENT OPTIONS. NEW THERAPIES ARE REQUIRED, BUT RESEARCH EFFORTS ARE STYMIED BY AN INABILITY TO ASSESS PRECURSOR PATHOLOGIES ADEQUATELY. IN PARTICULAR, METHODS FOR IMAGING THE HEALTH OF BLOOD VESSELS THAT SUPPLY REGIONS THREATENED BY DEGENERATION COULD PROVIDE A MEANS OF IDENTIFYING NEW THERAPEUTIC TARGETS. THIS PROPOSAL MEETS THIS NEED BY DEVELOPING A NEW INSTRUMENT THAT WILL BE ABLE TO CHARACTERIZE VASCULAR FUNCTION IN UNSURPASSED DETAIL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023008I NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY FREYA MOWAT, PHD, ENTITLED: (M2023010N) RELEVANT GENE-DIET INTERACTIONS IN AMD: USE OF A MOUSE MODEL TO STUDY THE COMBINED EFFECTS OF AGE, HIGH GLYCEMIC DIET AND PGC1A INSUFFICIENCY. INVESTIGATOR'S SUMMARY: HUMAN AGE-RELATED MACULAR DEGENERATION (AMD) HAS MANY RISK FACTORS INCLUDING AGE, GENETICS, AND UNHEALTHY LIFESTYLE. COMBINING RISK FACTORS INCREASES THE CHANCE OF AMD. WE WILL STUDY THE COMBINED EFFECTS OF RISK FACTORS (AGING, GENETIC VARIANT IN A MITOCHONDRIAL REGULATOR, AND HIGH DIETARY GLUCOSE) IN AN ANIMAL MODEL. WE WILL DETERMINE THE EFFECT ON VISION, RETINAL STRUCTURE, DNA METHYLATION, GENE EXPRESSION, AND METABOLIC FUNCTION IN THE EYE. WE PREDICT THAT A COMBINATION OF ALL 3 RISK FACTORS WILL CAUSE THE DEVELOPMENT OF AMD-LIKE DISEASE, AND WE WILL DEFINE BIOLOGICAL PATHWAYS THAT ACT IN CONCERT TO INCREASE AMD RISK. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023010N NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF IOWA. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY KELLY MULFAUL, PHD, ENTITLED: (M2023011N) INVESTIGATING HUMAN CHOROIDAL MACROPHAGE RECRUITMENT AND ACTIVATION IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF BLINDNESS WORLDWIDE. THE BACK OF THE EYE IS MADE UP OF CELL LAYERS THAT SUPPORT ONE ANOTHER SUPPLYING NUTRIENTS AND IMPORTANT MOLECULES THAT ARE REQUIRED FOR NORMAL VISION. IN AMD, THE OUTER SUPPORTING LAYER, THE CHOROID, IS DAMAGED. IMMUNE CELLS MOVE FROM THE CIRCULATION INTO CHOROID TISSUE IN RESPONSE TO DAMAGE TO PROTECT THE TISSUE. WE PREDICT THAT RECRUITED IMMUNE CELLS DO MORE DAMAGE THAN GOOD AND MAY BE INVOLVED IN THE DEATH OF THE CHOROID. WE AIM TO UNDERSTAND HOW THESE IMMUNE CELLS MOVE FROM THE CIRCULATION INTO THE TISSUE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023011N NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF TEXAS AT AUSTIN. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY LYNDSAY LEACH, PHD, ENTITLED: (M2023012N) TOWARD UNCOVERING THE INTRICACIES OF INTRINSIC RPE REPAIR: IDENTIFYING IMMUNE-RELATED PRO-REGENERATIVE FACTORS USING ZEBRAFISH RPE INJURY PARADIGMS. INVESTIGATOR'S SUMMARY: MAMMALS, INCLUDING HUMANS, HAVE A LIMITED ABILITY TO REPAIR RPE TISSUE LOST TO INJURY OR DEGENERATIVE DISEASES LIKE AGE-RELATED MACULAR DEGENERATION. CONSEQUENTLY, LITTLE IS KNOWN ABOUT WHAT CELLULAR AND MOLECULAR PROCESSES DRIVE RPE REGENERATION. THIS STUDY UTILIZES ZEBRAFISH, A VERTEBRATE MODEL CAPABLE OF ROBUST TISSUE REPAIR, TO BETTER UNDERSTAND THE IMMUNE-RELATED RESPONSES UNDERLYING RPE REGENERATION AND CHRONIC RPE DAMAGE. THE PROPOSED RESEARCH WILL UNCOVER NOVEL RPE PRO-REGENERATIVE FACTORS, WHICH HOLD POTENTIAL AS FUTURE THERAPEUTIC TARGETS TO QUELL, OR EVEN REVERSE, RPE LOSS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023012N NAME OF ORGANIZATION OR GOVERNMENT: YALE UNIVERSITY. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ABDELILAH MAJDOUBI, PHD, ENTITLED: (M2023013F) DECIPHERING THE INFLAMMATORY PATHWAYS TRIGGERING AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THE FACTORS THAT LEAD TO CHRONIC INFLAMMATION AND VISION LOSS IN AGE-RELATED MACULAR DEGENERATION ARE NOT WELL UNDERSTOOD. PREVIOUS GENETIC STUDIES HIGHLIGHTED THE ROLE OF INFLAMMATORY MICROGLIA IN THE DISEASE. HOWEVER, AS THESE CELLS ARE RARE IN THE RETINA, DEEP GENETIC ANALYSIS IS NEEDED TO UNDERSTAND THE MECHANISM BY WHICH THESE CELLS CONTRIBUTE TO THE DISEASE. THE AIM OF THIS STUDY IS TO IDENTIFY DISTINCT SUBPOPULATIONS OF MICROGLIA AND DEFINE THE GENETIC FACTORS THAT REGULATE OR REINFORCE THEIR ROLE IN THE RETINAL INFLAMMATION, WHICH CAN HELP IDENTIFY POTENTIAL THERAPEUTIC TARGETS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2023013F
SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:	NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DOROTA SKOWRONSKA-KRAWCZYK, PHD, ENTITLED: (M2020271) ROLE OF ELOVL2 IN AGE RELATED CHANGES IN THE EYE. EMERGENCY RELIEF SUPPLEMENT DUE TO COVID-19. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2020271 NAME OF ORGANIZATION OR GOVERNMENT: HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION. (H) PURPOSE OF GRANT: 2022 HELEN KELLER PRIZE FOR VISION RESEARCH PARTNERSHIP. THE HELEN KELLER PRIZE FOR VISION RESEARCH RECOGNIZES SIGNIFICANT ACCOMPLISHMENTS IN VISION RESEARCH, AND PROVIDES FUNDS FOR CONTINUANCE OF THOSE STUDIES. NAME OF ORGANIZATION OR GOVERNMENT: HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION. (H) PURPOSE OF GRANT: 2022 CONFERENCE SUPPORT. NAME OF ORGANIZATION OR GOVERNMENT: ARVO FOUNDATION FOR EYE RESEARCH. (H) PURPOSE OF GRANT: 2022 EYEFIND RESEARCH GRANT SPONSORSHIP NAME OF ORGANIZATION OR GOVERNMENT: ARVO FOUNDATION FOR EYE RESEARCH. (H) PURPOSE OF GRANT: 2022 TRAVEL GRANTS FOR CONFERENCE ATTENDEES

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990) 2021

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
MediumBullet

Attach to Form 990.
MediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I

Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
(1) NATIONAL DEVELOPMENT LLC 22512 GATEWAY CENTER DRIVE CLARKSBURG,MD20871 23-7337229	PROPERTY RENTAL AND MANAGEMENT	MD	523,842	3,820,008	BRIGHTFOCUS FOUNDATION
(2) AMERICAN HEALTH ASSISTANCE LLC 22512 GATEWAY CENTER DRIVE CLARKSBURG,MD20871 23-7337229	OWNER OF BRIGHTFOCUS HEADQUARTERS	MD	0	3,203,678	BRIGHTFOCUS FOUNDATION

Part II

Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2021

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?		(k) Percentage ownership
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No	(k) Percentage ownership

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	(i) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	Yes	No

Schedule R (Form 990) 2021

Page 3

Part V

Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity .....................

b Gift, grant, or capital contribution to related organization(s) ............................

c Gift, grant, or capital contribution from related organization(s) ............................

d Loans or loan guarantees to or for related organization(s) ............................

e Loans or loan guarantees by related organization(s) ............................

f Dividends from related organization(s) ............................

g Sale of assets to related organization(s) ............................

h Purchase of assets from related organization(s) ............................

i Exchange of assets with related organization(s) ............................

j Lease of facilities, equipment, or other assets to related organization(s) .......................

k Lease of facilities, equipment, or other assets from related organization(s) ......................

l Performance of services or membership or fundraising solicitations for related organization(s) .....................

m Performance of services or membership or fundraising solicitations by related organization(s) .................

n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) ...................

o Sharing of paid employees with related organization(s) ............................

p Reimbursement paid to related organization(s) for expenses ............................

q Reimbursement paid by related organization(s) for expenses ............................

r Other transfer of cash or property to related organization(s) ............................

s Other transfer of cash or property from related organization(s) ............................

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved

Schedule R (Form 990) 2021

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(e) Are all partners section 501(c)(3) organizations?		(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?		(k) Percentage ownership
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No	(k) Percentage ownership

Schedule R (Form 990) 2021

Page 5

Part VII

Supplemental Information

Provide additional information for responses to questions on Schedule R. See instructions.

Return Reference	Explanation

Schedule R (Form 990) 2021

Additional Data

Software ID:
Software Version:

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	46,522,410	43,451,535
9	Program service revenue (Part VIII, line 2g) .........	0	0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	3,244,235	-268,284
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	991,083	710,546
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	50,757,728	43,893,797
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	23,651,211	14,321,603
14	Benefits paid to or for members (Part IX, column (A), line 4).....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	5,534,304	6,392,782
16a	Professional fundraising fees (Part IX, column (A), line 11e) .....	798,203	942,971
b	Total fundraising expenses (Part IX, column (D), line 25) 11,417,976
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	24,073,639	26,850,858
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	54,057,357	48,508,214
19	Revenue less expenses. Subtract line 18 from line 12.......	-3,299,629	-4,614,417
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	65,540,964	58,626,477
21	Total liabilities (Part X, line 26).............	36,521,089	35,064,709
22	Net assets or fund balances. Subtract line 21 from line 20.....	29,019,875	23,561,768

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 19,544,776 including grants of $ 7,755,537 ) (Revenue $ )
	ALZHEIMER'S DISEASE RESEARCH (ADR)PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR ALZHEIMER'S DISEASE RESEARCH.

4b	(Code: ) (Expenses $ 9,259,355 including grants of $ 4,039,275 ) (Revenue $ )
	MACULAR DEGENERATION RESEARCH (MDR)PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR MACULAR DEGENERATION RESEARCH.

4c	(Code: ) (Expenses $ 3,630,550 including grants of $ 2,526,790 ) (Revenue $ )
	NATIONAL GLAUCOMA RESEARCH (NGR) PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR NATIONAL GLAUCOMA RESEARCH.

4d	Other program services (Describe in Schedule O.)
	(Expenses $ including grants of $ ) (Revenue $ )
4e	Total program service expenses32,434,681

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)		(D) Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
(A) Name and title
(18) AYO ABRAHAM CPA CGMA........................................................................ CONTROLLER	40.00 .......................	X	141,525	0	15,244
(19) LISA MORGAN........................................................................ DIRECTOR OF ANNUAL GIVING	40.00 .......................	X	120,019	0	33,191
(20) SHARYN ROSSI PHD DIR OF........................................................................ SCIENT. PROGRAMS, NEUROSCIENCE	40.00 .......................	X	117,521	0	34,655
(21) KACI BAEZ........................................................................ VP, INTEGRATED MARKETING & COMMS	45.00 .......................	X	121,016	0	18,929
(22) PREETI SUBRAMANIAN PHD DIR........................................................................ OF SCIENT. PROGRAMS, VISION SCIENCE	40.00 .......................	X	125,051	0	14,295

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)...........	1,908,513	0	349,839

1	Briefly describe the organization’s mission or most significant activities: BRIGHTFOCUS FOUNDATION (BRIGHTFOCUS) SEEKS A WORLD FREE FROM DISEASES OF MIND AND SIGHT.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	10
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	10
5	Total number of individuals employed in calendar year 2021 (Part V, line 2a) ......	5	68
6	Total number of volunteers (estimate if necessary) .............	6	60
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	0
b	Net unrelated business taxable income from Form 990-T, Part I, line 11 .........	7b	0

1a	Federated campaigns..		1a	257,616
b	Membership dues..		1b
c	Fundraising events..		1c	242,498
d	Related organizations		1d
e	Government grants (contributions)		1e

f	All other contributions, gifts, grants, and similar amounts not included above		1f	42,951,421

g	Noncash contributions included in lines 1a - 1f:$		1g	468,968

h Total. Add lines 1a-1f.......		43,451,535

		Business Code
2a
b
c
d
e
f	All other program service revenue.
g	Total. Add lines 2a–2f .....

3 Investment income (including dividends, interest, and othersimilar amounts) ......			882,169			882,169
4 Income from investment of tax-exempt bond proceeds
5 Royalties...........			495,958			495,958
		(ii) Personal	(i) Real
6a	Gross rents		594,742	6a
b	Less: rental expenses		70,900	6b
c	Rental income or (loss)		523,842	6c
d	Net rental income or (loss).......			523,842			523,842
		(ii) Other	(i) Securities
7a	Gross amount from sales of assets other than inventory		13,781,625	7a
b	Less: cost or other basis and sales expenses		14,932,078	7b
c	Gain or (loss)		-1,150,453	7c
d	Net gain or (loss).........			-1,150,453			-1,150,453
8a	Gross income from fundraising events (not including $ 242,498of contributions reported on line 1c). See Part IV, line 18 ....
			8a	63,800
b	Less: direct expenses ...		8b	373,054
c	Net income or (loss) from fundraising events..			-309,254			-309,254
9a	Gross income from gaming activities. See Part IV, line 19 ...
			9a
b	Less: direct expenses ...		9b
c	Net income or (loss) from gaming activities..
10a	Gross sales of inventory, less returns and allowances ..
			10a
b	Less: cost of goods sold ..		10b
c	Net income or (loss) from sales of inventory..
Business Code			Miscellaneous Revenue
11a
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......
12	Total revenue. See instructions.....			43,893,797	0	0	442,262

1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21 ....	11,712,740	11,712,740
2	Grants and other assistance to domestic individuals. See Part IV, line 22 ...........	6,000	6,000
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16. .............	2,602,863	2,602,863
4	Benefits paid to or for members .......
5	Compensation of current officers, directors, trustees, and key employees ...........	1,517,616	880,227	341,164	296,225
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) .........
7	Other salaries and wages........	3,630,029	1,993,650	1,131,056	505,323
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	206,463	113,392	64,330	28,741
9	Other employee benefits .......	696,236	382,380	216,935	96,921
10	Payroll taxes ...........	342,438	188,071	106,697	47,670
11	Fees for services (non-employees):
a	Management ......
b	Legal .........	107,489	51,197	56,292
c	Accounting ...........	102,567	55,371	35,038	12,158
d	Lobbying ...........
e	Professional fundraising services. See Part IV, line 17	942,971			942,971
f	Investment management fees ......	327,036		327,036
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)	2,129,159	1,952,570	146,845	29,744
12	Advertising and promotion ....	889,360	364,825		524,535
13	Office expenses .......	1,485,870	699,697	401,524	384,649
14	Information technology ......	970,074	686,028	189,425	94,621
15	Royalties ..
16	Occupancy ...........	480,975	281,749	154,310	44,916
17	Travel ............	421,586	276,164	98,187	47,235
18	Payments of travel or entertainment expenses for any federal, state, or local public officials .
19	Conferences, conventions, and meetings ....	513,887	493,989	13,435	6,463
20	Interest ...........	2,624	1,537	842	245
21	Payments to affiliates .......
22	Depreciation, depletion, and amortization ..	449,785	258,679	135,126	55,980
23	Insurance ...	108,539	40,215	57,615	10,709
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	PUB. AWARENESS POSTAGE	7,867,415	3,904,619	533,044	3,429,752
b	PUB. AWARENESS PRINTING	7,290,443	3,640,583	445,165	3,204,695
c	PUB. AWARENESS COMP.	2,121,383	1,069,157	115,067	937,159
d	LIST RENTAL	1,582,666	778,978	86,424	717,264
e	All other expenses
25	Total functional expenses. Add lines 1 through 24e	48,508,214	32,434,681	4,655,557	11,417,976
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).	18,131,282	8,101,074	1,241,396	8,788,812

1	Cash–non-interest-bearing ........			138,432	1	205,653
2	Savings and temporary cash investments .........			4,940,634	2	3,889,254
3	Pledges and grants receivable, net ......			6,568,692	3	6,522,988
4	Accounts receivable, net .............			0	4	165,585
5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .......
					5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) ...
					6
7	Notes and loans receivable, net ...........				7
8	Inventories for sale or use ............			37,046	8	51,738
9	Prepaid expenses and deferred charges ......			322,345	9	50,244
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	13,067,892
b	Less: accumulated depreciation	10b	4,939,613	8,161,115	10c	8,128,279
11	Investments—publicly traded securities .			45,203,665	11	39,542,541
12	Investments—other securities. See Part IV, line 11 .....				12
13	Investments—program-related. See Part IV, line 11 ..				13
14	Intangible assets ...............				14
15	Other assets. See Part IV, line 11 ...........			169,035	15	70,195
16	Total assets. Add lines 1 through 15 (must equal line 33)...			65,540,964	16	58,626,477

17	Accounts payable and accrued expenses .....	862,205	17	1,112,727
18	Grants payable ...	34,865,851	18	33,119,925
19	Deferred revenue .........	0	19	116,500
20	Tax-exempt bond liabilities .........		20
21	Escrow or custodial account liability. Complete Part IV of Schedule D		21
22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .........
			22
23	Secured mortgages and notes payable to unrelated third parties ..		23
24	Unsecured notes and loans payable to unrelated third parties ..		24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D	793,033	25	715,557
26	Total liabilities. Add lines 17 through 25..	36,521,089	26	35,064,709

	Organizations that follow FASB ASC 958, check here and complete lines 27, 28, 32, and 33.
27	Net assets without donor restrictions ..........	13,864,090	27	10,360,299
28	Net assets with donor restrictions ...........	15,155,785	28	13,201,469
	Organizations that do not follow FASB ASC 958, check here and complete lines 29 through 33.
29	Capital stock or trust principal, or current funds .....		29
30	Paid-in or capital surplus, or land, building or equipment fund ...		30
31	Retained earnings, endowment, accumulated income, or other funds		31
32	Total net assets or fund balances ...........	29,019,875	32	23,561,768
33	Total liabilities and net assets/fund balances ........	65,540,964	33	58,626,477

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to separately file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990). . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471). . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621) .	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships (see Instructions for Form 8865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990).. . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No